Document:

Exhibit 10.2

 

ASSET ASSIGNMENT AGREEMENT

 

ACTIVUS PHARMA CO., LTD

A Japanese Company

("Assignor")

 

- and -

 

MARIPOSA HEALTH PTY LTD 

(ACN 134 154 680)

("Assignee")

 

Ref: KJD:197366

Version:14 August 2010

 

    	 

    	 

    

 

TABLE OF CONTENTS

 

	1.	INTERPRETATION	1
	2.	PRE-CONDMONS	5
	3.	ASSIGNMENT OF INTELLECTUAL PROPERTY AND ASSIGNORS TECHNOLOGY	6
	4.	ASSIGNMENT OF RIGHTS IN THE DIC AGREEMENT	7
	5.	CONSIDERATION	8
	6.	DELIVERY	8
	7.	RIGHTS AND OBLIGATIONS OF THE PARTIES PENDING THE EFFECTIVE DATE	9
	8.	UNDERTAKING AND WARRANTIES	10
	9.	NON-USE OF THE INTELLECTUAL PROPERTY BY THE ASSIGNOR	12
	10.	AUTHORITIES	13
	11.	UNDERTAKINGS AND INDEMNITY	13
	12.	CONSULTING SERVICES	14
	13.	SEVERABILITY	14
	14.	NEW SOUTH WALES LAW AND JURISDICTION	15
	15.	AMENDING THIS AGREEMENT	15
	16.	THIS IS THE ENTIRE AGREEMENT	15
	17.	EACH PARTY MUST DO WHATEVER IS NECESSARY	15
	18.	No WAIVER	15
	19.	TAXATION	16
	20.	GIVING A NOTICE	16
	21.	TERM OF OBLIGATIONS IN CLAUSE 4.1	16
	22.	PUBLIC ANNOUNCEMENTS	17
	23.	COUNTERPARTS	17
	24.	TRANSFER OR ASSIGNMENT OF THIS AGREEMENT	17
	25.	EXCHANGE	17

 

SCHEDULES

 

SCHEDULE-1 

Effective Date 

Patents

 

SCHEDULE-2 

		1.	Data, information and documentation

1-1. The documentation managed
by Activus Phamia

1-2. Agreements for Assignment with CROs and CMOs

		2.	Chemical Samples

 

SCHEDULE-3

DIC Agreement

 

SCHEDULE-4

DIC Acknowledgement

 

SCHEDULE-5 

Sosei Consent

 

    	 

    	 

    

 

THIS AGREEMENT is made the 16th day of August,
2010

 

	BETWEEN:	ACTIVUS PHARMA CO., LTD, a Japanese
    Company, of Venture Plaza Funabashi 218, 1-17-25, Kita-honcho, Funabashi-shi, Chiba 273-0864, Japan ("Assignor")
	 	 
	AND:	MARIPOSA HEALTH PTY LTD (ACN 134 154 680) of 11 Algona Street, Bilgola Plateau 2107, New South Wales, Australia ("Assignee")

 

RECITALS

 

		A.	The Assignor is the absolute owner of the Assignor's Technology and all Intellectual Property in relation to the Assignor's
Technology, including:

 

		(i)	Copyright;

 

		(ii)	Patents;

 

		(iii)	Works; and

 

		(iv)	Confidential Information.

 

		B.	In consideration for the payments specified in clause 5 of this Agreement, the Assignor has agreed to assign its ownership
of the Assignors Technology and the Intellectual Property to the Assignee as from the Effective Date,

 

		C.	The parties wish to formally record the assignment of the ownership of the Intellectual Property on the terms of this Agreement.

 

AGREEMENT

 

		1.	Interpretation

 

		1.1	In this Agreement:

 

		(a)	"Activus Contracts" means the agreements that Activus has entered into with third
parties that relate to the Assignor's Technology by way of either:

 

assuming the agreements from DIC under the DIC Agreement;
or

 

		(ii)	entering into the agreements independently after the Date of Assignment defined in the DIC Agreement, and

 

including but not limited to those agreements set
out in item 1-2 of Schedule 2;

 

		(b)	"Agreement" means this agreement and includes any Schedule or Annexure to it;

 

    	 

    	-2-

    

 

		(c)	"Australian Taxes" means all taxes incurred as a consequence of entering the Agreement
that are imposed by an Australian revenue office or similar body.

 

		(d)	'Assignor's Technology" means:

 

		(i)	the existing data, information, documentation, laboratory notebooks, reports, test reports, chemical samples and associated
records that are owned by the Assignor or are in the possession or control of the Assignor as of the Effective Date in relation
to the reductone molecule technology known by the term TA-270 ("Product") and are set forth or described in Schedule-2
in relation to the Product and / or as described in the subject matter of the Patents;

 

		(ii)	all existing chemical compounds comprising the Product;

 

the existing related chemical compounds as described
in the subject matter of the Patents ("Related Compound");

 

		(iv)	all existing technology related to or derived from the Patents, including the procedures, techniques, knowhow, manufacturing
processes and applications of the Patents;

 

		(v)	all such rights referred to in (i) to (iv) that arise under or are referred to in the Activus Contracts; and

 

		(vi)	all other rights transferred or assigned to the Assignor in relation to the TA-270 technology and Assets (as defined in the
DIC Agreement) under the DIC Agreement.

 

		(e)	"Business Day" means Monday to Friday, excluding public holidays in the State
of New South Wales, Australia and in Japan;

 

		(f)	"Confidential Information" means:

 

all technical knowledge and information,
operating and testing methods and procedures, practices and know-how relating to the Assignor's Technology;

 

		(ii)	all ideas, product concepts, prototypes, physical dimensions, designs, manufacturing and production processes, computer programs
and databases, recipes, ingredients, chemical compositions, chemical samples, formulations, written materials, laboratory notebooks,
research reports, manuals, diagrams, pictures and drawings, specifications, notes, calculations, know how or any other verbal information
or written data concerning or relating to the Assignor's Technology;

 

		(iii)	all inventions, improvements, modifications, discoveries, developments, techniques arising
                                                                 from or relating to the Assignor's Technology to the extent
they are already conceived as of the Effective Date;

 

    	 

    	-3-

    

  

		(iv)	all other information relating to the Assignor's Technology which, either is not in the public domain or by its nature, places
or potentially places the Assignor at an advantage over its present or future business competitors,

 

whether or not marked "Confidential"
BUT does not include information which:

 

		(v)	prior to the assignment effected by this Agreement is already in the public domain; or

 

		(vi)	after the assignment effected by this Agreement becomes part of the public domain other than by disclosure in breach of the
terms of this Agreement;

 

		(9)	"Consideration" means the amount of JPY55,000,000;

 

		(h)	"Copyright" means all copyright in the Works;

 

		(i)	"DIC Acknowledgement" refers to the DIC Acknowledgement and Confirmation by Mariposa to be executed by DIC
and acknowledged and accepted by Mariposa and Activus substantially in the form as appears in Schedule 4 hereto;

 

		(E)	"DIC Corporation" means DIC Corporation, formerly known as Dainippon Ink and Chemicals, Incorporated, having
its principal place of business at DIC Building, 7-20, Nihonbashi 3-chome, Chuo-ku, Tokyo 103-8233, Japan;

 

		(k)	"DIC Agreement" means the agreement dated 31 October 2006 between DIC Corporation and the Assignor, a copy
of which appears in Schedule 3 hereto, to the extent it is related to the Product, the Patents and the Assignor's Technology (DIC
Agreement being attached hereto);

 

		(I)	"Effective Date" means the earlier of the date specified in Schedule-1 or the date being 3 Business Days from
the date the Assignee notifies the Assignor in writing that the Pre Conditions in clause 2 have been met in accordance with that
clause 2.2;

 

		(m)	"GST Act' means A New Tax System (goods and Services Tax) Act 1999

 

		(n)	"Intellectual Property" means all Intellectual Property Rights arising from or relating to the Assignor's
Technology, including but not limited to:

 

		(i)	the Patents, the Copyright, the Works and the Confidential Information;

 

		(ii)	all other rights resulting from intellectual activity relating to the Assignor's Technology;

 

    	 

    	-4-

    

 

		(o)	"Intellectual Property Rights" means all intellectual property rights, including but not limited to the following
rights:

 

patents, copyright, and any right
to have confidential information kept confidential; and

 

		(ii)	any application or right to apply for registration of any of the rights referred to in sub-paragraph
(i);

 

		(iii)	the right to apply for registration of a patent application, and to own all registrations derived
therefrom including reissues, extensions, confirmations, re-examinations, and inventor's certificates;

 

		(iv)	the right to sue and claim and retain damages and other remedies, including but not limited to
an account of profits, for infringements of and/or wrongful interferences to a patent application and / or patent or copyright
work, whether or not such rights arose before the date of this Agreement; and

 

		(v)	all rights, powers, liberties and immunities conferred on the proprietor of the patents, patent
applications and copyright works;

 

		(p)	"Japanese Taxes" means all taxes incurred as a consequence of entering the Agreement that are imposed by a
Japanese revenue office or similar body.

 

		(q)	"party" means a party to this Agreement and "parties" means both of them;

 

		(r)	"Patents" means:

 

		(i)	the registered patents described in the Schedule-1;

 

		(ii)	all applications for a patent described in the Schedule-1 (including ail inventions, innovations
and all other subject matter described in them) which subsist at the date of this Agreement; and

 

		(iii)	all patents and patent applications corresponding to the patents and/or patent applications referred
to in Clause 1.10) and Clause 1.1r(ii), and including without limitation, all rights of priority, and all divisional and continuation
applications, reissue patents and other such corresponding patents and patent applications, whether or not applied for, or issued,
after the date of this Agreement"

 

		(iv)	all subsequently granted or issued patents resulting from a patent referred to in clauses 1.1(r)(ii)
and 1.1(r)(iii);

 

    	 

    	-5-

    

 

		(s)	"Sosei" means Sosei Group Corporation of Kojimachi Tsuruya Hachiman Bldg. 5F 2-4 Kojimachi, Chiyodaku-ku,
Tokyo 102-0083 Japan;

 

		(t)	"Sosei Consent" means the Sosei Consent letter in the form attached to Schedule 5; and

 

		(u)	"Works" means all hard copy and electronic (including computerised) literary, artistic and other works and
subject matter (including without limitation all documents, drawings, written reports, computer programs and manuals, object code
and source code) concerning or relating to the Assignor's Technology;

 

		1.2	In this Agreement, the following rules apply, unless the context requires otherwise:

 

		(a)	headings are for convenience only and do not affect the interpretation of this Agreement;

 

		(b)	the singular includes the plural and the plural includes the singular;

 

		(c)	any gender includes any other gender;

 

		(d)	any thing required to be done on a day that is not a Business Day, may be done on the next Business Day;

 

		(e)	reference to a person includes a natural person, corporation, partnership, association or other legal entity;

 

reference to legislation includes
that legislation as amended or modified or re-enacted;

 

		(g)	reference to a provision, clause, Schedule or Annexure means, respectively, a provision, clause, Schedule or Annexure of this
Agreement.

 

		2.	Pre-conditions

 

		2.1	This Agreement is conditional upon and subject to the Assignee:

 

		(a)	conducting and completing, to its sole satisfaction, due diligence of the Assignor's Technology
and Intellectual Property prior to the Effective Date; and

 

		(b)	receiving signed DIC Acknowledgement and Sosei Consent in forms to the Assignee's sole satisfaction
("Pre-conditions").

 

		2.2	The Assignee shall conduct and complete due diligence and shall determine whether the Preconditions have been met and shall
provide the Assignor the written notice not less than 3 days prior to the date specified in Schedule-1 ("Due Diligence Termination
Date").In the event that the Assignee fails to give the Assignor such notice to the effect that the Preconditions have been
met prior to the Due Diligence Termination Date, this Agreement shall then automatically terminate as of the Effective Date. It
is confirmed that upon such termination, both parties release and forever discharge each other from any claim or liability arising
out of or in connection with this Agreement.

 

    	 

    	-6-

    

  

		3.	Assignment of Intellectual Property and Assignors Technology

 

		3.1	In the event that the Assignee gives the Assignor the notice to the effect that the Pre-conditions have
been met prior to the Due Diligence Termination Date ("Event Occurs'), the Assignor assigns and transfers the Intellectual
Property and the Assignor's Technology absolutely to the Assignee with effect as and from the Effective Date. The Assignor assigns
to the Assignee, and the Assignee accepts its full right, title and interest in and to:

 

		(a)	the Copyright throughout the world and all other rights of a similar nature now subsisting or conferred
in respect of the Works by the law in force in any part of the world including all renewals and extensions;

 

		(b)	by way of assignment of future copyright, the Copyright and all other rights of a like nature from
time to time belonging to the Assignor which may be conferred or may subsist in any alterations, additions or adaptations to the
Works and any and all renewals and extensions of them;

 

		(c)	the Patents (whether or not granted);

 

		(d)	any and all common law and statutory rights and remedies in relation to the Patents available to
the Assignor at the Effective Date;

 

		(e)	the Confidential Information;

 

		(U	any and all common law and statutory rights and remedies in relation to the Confidential Information
available to the Assignor at the Effective Date;

 

		(9)	all claims, demands, causes of action for infringement or otherwise, whether past or present, against
any third party, and all rights to costs, damages profits or other remedy that may be available in respect of the Intellectual
Property;

 

		(h)	the Intellectual Property; and

 

the Assignors
Technology.

 

		3.2	In case that the Event Occurs, the Assignor agrees that, as and from the Effective Date, the Assignor has no right:

 

		(a)	to argue or raise any moral rights that it may have in the Intellectual Property and hereby waives
any such rights; or

 

		(b)	to prevent the Assignee from using and exploiting the Intellectual Property in any way it determines.

 

    	 

    	-7-

    

 

		4.	Assignment of rights in the DIC Agreement

 

		4.1	In case that the Event Occurs, with effect as and from the Effective Date, the Assignor assigns
and transfers absolutely to the Assignee all rights contained in the DIC Agreement and the obligations and effects set out in Sections
4, 7, 9, 10(1), 10(2) and 10(3) of the DIC Agreement, and clause(e) v) of the DIC Acknowledgement (these being the only obligations
transferred from Activus to Mariposa), to the extent that they refer or relate to the Assignor's Technology and Intellectual Property.
For the avoidance of doubt, this Agreement does not in any way transfer the DIC Agreement or any liabilities or obligations under
the DIC Agreement other than the ones outlined in the DIC Acknowledgement,

 

		4.2	The Assignor acknowledges and agrees that the Assignee assumes no obligations, to DIC Corporation
other than those set out in DIC Acknowledgement.

 

		4.3	The Assignor acknowledges that the Assignee assumes no obligations, liabilities, risk or burden
under the Activus Contracts.

 

		4.4	In relation to the Activus Contracts, the Assignor agrees to assign or transfer any Activus Contract
requested by the Assignee on the following basis:

 

		(a)	where the third party to the Activus Contract's consent is not required for such assignment, on
notification in writing by the Assignee the assignment will occur automatically unless required in writing by the Assignor in which
case the Assignor will sign any document and do any such act required to transfer the Activus Contract, including, but not limited
to signing any forms set out in Schedule 2, 1-2; and

 

		(b)	where the third party to the Activus Contract's consent is required for such assignment, the Assignor
will use its best endeavours and do all acts in its power to obtain the third party's consent to the transfer or assignment of
the Activus Contract as soon as practicable after notification by the Assignee, including, but not limited to signing any forms
set out in Schedule 2, 1-2.

 

		4.5	The Assignor warrants that:

 

		(a)	Sosei has agreed to acquire 100% of Activus, which will complete on 17 August 2010, and Sosei is
aware of and has consented to the Assignor assigning the Assignor Technology and Intellectual Property pursuant to the terms of
this Agreement and that no further consent from Sosei is required to any matter in the Agreement;

 

		(b)	the DIC Agreement represents the entire agreement between the Assignor and DIC Corporation, and
there is no other agreement, understanding, warranty or representation, whether oral or written, binding the Assignor or DIC Corporation
concerning any aspect of the DIC Agreement;

 

    	 

    	-8-

    

 

		(c)	there is no existing breach of the DIC Agreement, nor any event giving rise to a breach of the
DIC Agreement by either party; and

 

		(d)	the DIC Agreement has not been modified, supplemented, varied or amended prior to the Effective
Date.

 

		4.6	The Assignor warrants that it will be responsible for (and must indemnify the Assignee from) any and all claims arising
out of or associated with the Assignor's conduct and the D1C Agreement:

 

		(a)	prior to the Effective Date; and

 

		(b)	after the Effective Date, other than in relation to those obligations assumed by the Assignee,
being the obligations set out clauses 4, 7 (3), 10(1) and 10(2) of the DIC Agreement and the effects set out clauses 7 (1) , 7
(2), 9, to the extent that they refer or relate to the Assignor's Technology and Intellectual Property.

 

		5.	Consideration

 

		5.1	Within 5 Business Days of the date of this Agreement the Assignee will pay the Consideration into the following secured account
of the Assignee's Japanese lawyers as designated by the Assignees ("Trust Account"), to be held pending the satisfaction
of the Pre-conditions referred to in Clause 2 and then delivery of the Intellectual Property and Assignors Technology by the Assignor
to the Assignee in accordance with clause 6.

 

Trust Account :

 

Bank of Tokyo-Mitsubishi UFJ

Shin-marunouchi Branch

Ordinary Account: 3095389

Account holder: Ryugo Yoshimura (client deposit account)

 

(Client Deposit Account Title: kokyaku azukariguchi
ito mitomi horitsu jimusyo bengoshi yoshimura ryugo)

 

		5.2	The Consideration is payable by the Assignee to the Assignor upon confirmation in writing by the Assignee that the Pre-conditions
referred to in Clause 2 have been satisfied prior to the Effective Date and within a period of no later than 5 Business Days from
the Effective Date.

 

		6.	Delivery

 

		6.1	Within 5 Business Days from the Effective Date and in any event after the Event Occurs, the Assignor agrees to deliver up to
the Assignee signed transfers of the Intellectual Property forms previously prepared by the Assignor and/or as directed by the
Assignee or the Assignee's nominated patent attorney.

 

    	 

    	-9-

    

 

		6.2	Within 3 Business Days from any further request by the Assignee and in any event after the Event Occurs, and at the cost of
the Assignee, the Assignor agrees to execute any further assignment documents or confirmatory agreements (as appropriately completed)
or any other type of assignment which may be required to be lodged with any authority or government in any country or region of
the World, to reflect the assignment of any aspect of the Intellectual Property effected by this Agreement.

 

		6.3	The Assignee agrees to bear all the costs and expenses incurred in connection with record or registration of such assignment
in each Patent Office.

 

		6.4	Within 5 Business Days from the Effective Date and in any event after the Event Occurs, the Assignor agrees to:

 

		(a)	deliver the Intellectual Property and Assignor's Technology (other than the compounds unless so
directed by the Assignee) to the Assignee for shipment, and the Assignee agrees to take delivery of the Intellectual Property and
Assignor's Technology at the cost of the Assignee at the Assignor's place of business (Venture Plaza Funabashi 218, 1-17-25, kita-honcho,
Funabashi-shi, Chiba 2730864, Japan) through a carrier pre-arranged by the Assignee. Title and risk of loss to the Intellectual
Property and Assignor's Technology shall pass to the Assignee upon delivery thereof to the Assignee (or Assignee's representative
for purposes of shipment) at the Assignor's place of business; arid

 

		(b)	deliver up to the Assignee all material and media, whether hard copy, electronic or computerised
or otherwise, in its possession or control that depicts or evidences any part of the Intellectual Property or Assignor's Technology
at the Assignor's place of business; and

 

		(c)	deliver to the Assignee the original signed DIC Acknowledgement and original signed Sosei Consent;
and

 

		(d)	deliver to the Assignee the instruments set out in Schedule 2 duly executed by the parties thereto
other then the Assignee, on the understanding that the Assignee is under no obligation to sign the agreements set out in Schedule
2 item 1 - 2.

 

		7.	Rights and obligations of the parties pending the Effective Date

 

		7.1	In the period between the date of this Agreement and up to and including the Effective Date, the Assignor must:

 

		(a)	not incur any material liabilities in relation to the Assignors Technology and Intellectual Property
other than in the ordinary and proper course of carrying on the business of the Assignor and with the prior written consent of
the Assignee;

 

		(b)	maintain all usual relationships with present and potential customers, suppliers, licensors, licensees,
distributors and other third parties in relation to
the Assignors Technology and Intellectual Property;

 

    	 

    	-10-

    

 

		(c)	use best endeavours to preserve and maintain the Assignors Technology and Intellectual Property, including:

 

		(i)	maintaining the Patents by paying all costs associated with them including annuity and maintenance
fees due on 10 September 2010 for patent family 2 in Canada, China and Australia as set out in Schedule 1;

 

		(ii)	not in any way limiting or amending the claims of the Patents as at the date of this Agreement
without the written consent of the Assignee; and

 

		(iii)	not encumbering theAssignors Technology and Intellectual
Property in any manner whether by licence, option, assignment, or any other means; and

 

		(d)	consult and seek the written approval of the Assignee prior to making any decision that is, or is likely to be, material to
any of the Assignors Technology and intellectual Property.

 

		7.2	Where before the Effective Date an event occurs that has, or may have, a material effect on the prospects, operation
or value of the Assignors Technology and/or Intellectual Property, the Assignor must, immediately on becoming aware of that event,
give written notice to the Assignee fully describing the event.

 

		8.	Undertaking and Warranties

 

		8.1	Subject to clause 8.4, the Assignor warrants that:

 

		(a)	it is the originator, assignee, creator, author, inventor, or otherwise the owner of the Intellectual
Property;

 

		(b)	it has not charged or otherwise encumbered, granted licences or options, assigned either in whole
or in part, or in any other way dealt with the Intellectual Property in a manner inconsistent with its obligations under this Agreement;

 

		(C)	as of the Effective Date, the Assignor has no knowledge of use prior to the creation or any application
for registration of the Intellectual Property by any other person;

 

		(d)	as of the Effective Date and to the Assignor's knowledge, the development, manufacture, sale, or
use of the Product shall in no way infringe or constitute a misappropriation or other violation of the rights of a third party
to the extent the Product is used as described in the Intellectual Property;

 

		(e)	the inventions, methods and manner of manufacture protected by the Patents was not disclosed (other
than for secret use) nor commercially used or exploited
prior to the date of application of the Patents;

 

    	 

    	-11-

    

  

as of the Effective Date and
to the Assignor's knowledge, the Confidential Information has not been disclosed nor made available to any person who has not promised
to keep it confidential;

 

		(g)	the applications and registrations, as listed in the Schedule-1, of the Patents are current and
of full force and effect and that there are no existing or threatened challenges to the patent applications or registrations on
any grounds; and

 

		(h)	it has the right to transfer and assign the Assignor Technology and the Intellectual Property.

 

		8.2	Each party represents and warrants to the other.

 

		(a)	that it has the full authority to enter into this Agreement, and to carry out the transaction contemplated
herein in accordance with the terms hereof, and there is no consent required form a third party that has not already been given
and referred to in this Agreement;

 

		(b)	that this Agreement represents the valid and binding obligations that are enforceable against it
in accordance with the terms;

 

		(c)	that its execution hereof and performance hereunder does not and will not conflict with or violate
any statue, regulation or agreement to which it is subject; and

 

		(d)	that it is not aware of any impediment which would inhibit its ability to perform the terms imposed
on it by this Agreement

 

		8.3	The Assignor makes no representation or warranty that any filed patent applications of the Patents will result in issued patents,
but does warrant that the Assignor is not aware of any reason why any of the Patents will not result in the granting of a valid
patent.

 

		8.4	The Assignee acknowledges that the Patents are encumbered by the terms and conditions outlined in clause (d) of the DIC Acknowledgement,
insofar as the DIC Agreement relates to the TA-270 Product.

 

		8.5	The Assignee acknowledges that the transfer of the Assignors Technology and Intellectual Property did not constitute transfer
of the business of DIC pursuant to the DIC Agreement and DIC shall not bear the obligations of non-competition imposed on the transferor
by Article 16 of the Commercial Law as referred to in the DIC Agreement

 

		8.6	The Assignee acknowledges that DIC has not provided any warranties in the DIC Agreement to Activus that

 

		(a)	the Assignee implementing the Intellectual Property Rights relating to the Patents does not infringe the Intellectual Property
Rights, including patent rights, of a third party;

 

    	 

    	-12-

    

 

		(b)	the intellectual Property Rights relating to the Patents are not infringed by the third party;

 

		(c)	the submitted patent applications for the Patents will be granted. and

 

		(d)	the Intellectual Property Rights and the Patents are transferred to Activus on an "AS-IS" basis, and no warranty,
including with respect to quality, performance, credibility, reliability, no defects, were provided.

 

		8.7	The Assignor undertakes to indemnify and keep the Assignee indemnified from and against any and all claims, demands, losses,
damages, costs and expenses that the Assignee suffers or incurs as a result of any breach by the Assignor of the warranties contained
in this Agreement.

 

		8.8	On and from the Effective Date, the Assignor agrees to at the Assignee's cost

 

		(a)	provide the Assignee with access to the inventors of the Patents from time to time as may be required
for the purpose of supporting the validity and maintenance of the Patents; and

 

		(b)	keep the Assignee fully informed on a continuing basis of any prior art of which the Assignor may
become aware and which may be relevant to the Patents.

 

		9.	Non-use of the Intellectual Property by the Assignor

 

		9.1	On the Effective Date, the Assignor must not use in any way or exploit, reproduce, retain, store, record, computerise, document
or duplicate any part of the Intellectual Property, except where such is strictly necessary for legal, product safety or internal
good practice requirements.

 

		9.2	On and from the Effective Date, the Assignor must:

 

		(a)	not use or exploit any part of the Intellectual Property or aid or abet any other person to do
so other than as permitted by this Agreement or by the Assignee in writing;

 

		(b)	not allow any third party to have access to or possession of the Intellectual Property;

 

		(c)	maintain strict confidentiality in relation to the Confidential Information and must not divulge
any aspect of the Confidential Information to any third party ; and

 

		(d)	not promote, develop or exploit any product (using new intellectual property) owned by the Assignor
as of the Effective Date in the field of reductone technology as described in the Patents for the treatment or prevention of diseases
of the lung, including but not limited to chronic obstructive pulmonary disease and asthma.

 

    	 

    	-13-

    

 

		10.	Authorities

 

		10.1	Subject to the provisions in Section 7.1 hereof, the Assignor agrees at its expense to:

 

		(a)	execute all documents necessary to enable the Assignee to assign, apply for or obtain registration as the registered proprietor
or owner of the Intellectual Property; and

 

		(b)	render all assistance reasonably required by the Assignee for the purpose of confirming the Assignee's title to the Intellectual
Property and to maintain and establish the use, validity or registration of the Intellectual Property.

 

		10.2	Pursuant to the Assignee's obligations under the moral rights provisions of the Copyright Act
1968 (Cth) and any equivalent legislation under any country of the World, the Assignor, if the author of the Works, unconditionally,
irrevocably, genuinely and comprehensively consents in favour of the Assignee, for the Assignee to use, reproduce, adapt, communicate
and exercise all other copyrights which may subsist in the Works, in any manner or medium and without reference to the Assignor,
in any way whatsoever. To the extent possible in any country the Assignor agrees to waive any moral rights it has. Further to the
extent the moral rights are rights of a person who is an employee of, consultant to, associate of or otherwise known to the Assignor,
the Assignor will use best endeavours to procure consent and waiver by that person, as referred to in this clause.

 

		11.	Undertakings and Indemnity

 

11.1 The Assignor
undertakes not to do any act, nor assist any other person to do any act, which would or might:

 

		(a)	invalidate or put in dispute the Assignee's right, title and interest in and to any Intellectual
Property; or

 

		(b)	oppose any application for registration or renewal of any of the Intellectual Property, or invalidate
any registration or renewal of the Intellectual Property.

 

11.2 The Assignor
undertakes to indemnify and keep the Assignee indemnified from and against any and all claims, demands, losses, damages, costs
and expenses that the Assignee incurs or may incur as a result of a breach by the Assignor of the Assignor's obligations, representations
and warranties contained in this Agreement

 

11.3 Subject
to clause 11.4 the Assignee undertakes to indemnify and keep the Assignor indemnified from and against any and all claims, demands,
losses, damages, costs and expenses that the Assignor incurs or may incur as a result of:

 

		(a)	a breach by the Assignee of the Assignee's obligations, representations and warranties contained
in this Agreement; and

 

    	 

    	-14-

    

 

		(b)	the development, manufacture, marketing and sale of the Product or any other product covered by
the Patents by the Assignee, its licensee or distributors after the Effective Date.

 

11.4 The Assignee
shall not be liable to the Assignor hereunder for:

 

		(a)	indirect, incidental, consequential, special, or punitive damages, including without limitation
damages relating to lost profits or lost business opportunity, arising out of any act or omission hereunder except for acts or
omissions constituting gross negligence or wilful misconduct or

 

		(b)	any and all claims, demands, losses, damages, costs and expenses that the Assignor incurs or may
incur as a result of any action or inaction of the Assignee attributable to the period prior to the Effective Date,

 

11.5 Notwithstanding
anything herein to the contrary or any applicable law, the Assignor's maximum aggregate liability with respect to this agreement
or any matter related to or arising out of this Agreement under any contract, negligence, strict liability or other theory shall
not exceed the amount of the Consideration paid to and retained by the Assignor under this Agreement.

 

		12.	Consulting Services

 

12.1 For a
period of 3 months from the Effective Date, the Assignor agrees to provide at no cost to the Assignee various Patent registration
assistance, change of ownership, services responding to general enquiries relating to the Assignors Technology and technology transfer
services to the Assignee in relation to the Intellectual Property and Assignor Technology ("Consulting Services"), it
being confirmed that the Assignee shall not be responsible for the costs incurred in relation to the patent assignments and technology
transfer prior to the Effective Date.

 

12.2 Any additional
services in excess of 40 hours for the Consultancy Services that are expected or anticipated to result in significant cost to the
Assignor, or significant use of the Assignor's personnel resources, may be charged to the Assignee by the Assignor by agreement.

 

		13.	Severability

 

13.1 If a
provision (or part of it) is held to be unenforceable or invalid, then it must be interpreted as narrowly as necessary to allow
it to be enforceable or valid.

 

13.2 If a
provision (or part of it) is held to be unenforceable or invalid, then:

 

		(a)	the provision (or part of it) must be severed from this Agreement; and

 

		(b)	the remaining provisions (and remaining part of the provision) are valid and enforceable.

 

    	 

    	-15-

    

 

		14.	New South Wales law and jurisdiction

 

14.1 The law
of New South Wales, Australia from time to time governs this Agreement.

 

14.2 All disputes
arising out of or in connection with this Agreement will be finally settled under the Rules of Arbitration of the International
Chamber of Commerce by three arbitrators appointed in accordance with the said Rules. The arbitration will take place in
Sydney, Australia if demanded by the Assignor and in Tokyo, Japan if demanded by the Assignee, and will be conducted in the English
language. The award of the arbitrators will be final and binding on both Parties. The Parties bind themselves to carry out the
awards of the arbitrators.

 

14.3 Nothing
in this Clause 13 prevents a party from approaching the Courts for urgent interlocutory relief

 

		15,	Amending this Agreement

 

An amendment or change is only effective once it is
made in writing and executed by all parties.

 

		16.	This is the entire Agreement

 

This is the entire Agreement of the parties concerning
the subject matter of this Agreement. There is no other Agreement, understanding, warranty or representation, whether oral or written,
binding the parties concerning any aspect of this Agreement.

 

		17.	Each party must do whatever is necessary

 

17.1 Each
party must do whatever is necessary to give full effect to this Agreement, both before and after it is executed. This may include
executing a document or carrying out an act.

 

17.2 If a
party does not do whatever is necessary to give full effect to this Agreement after being requested to do so, that party irrevocably
appoints the other party as its attorney and in its name to do all things necessary (including executing documents or carrying
out an act) to give effect to this Agreement.

 

		18,	No waiver

 

18.1 A party
may exercise its rights at any time and does not waive those even if that party:

 

		(a)	previously waived a breach or default of all or part of the same or other provision; or

 

		(b)	delayed or omitted to exercise its rights.

 

18.2 A waiver is only effective:

 

		(a)	if it is signed by the party granting the waiver; and

 

    	 

    	-16-

    

 

		(b)	to the extent set out in the waiver.

 

		19.	Taxation

 

19.1 The
Assignor will be responsible for payment of all Japanese Taxes arising from this Agreement. To the extent that the Assignee is
liable for any Japanese Taxes arising from this Agreement, the Assignor will reimburse the Assignee for such amounts.

 

19.2 The Assignee
will be responsible for payment of all Australian Taxes arising from this Agreement. To the extent that the Assignor is liable
for any Australian Taxes arising from this Agreement, the Assignee will reimburse the Assignor for such amounts. At the Assignor's
request, the Assignee shall provide the Assignor a certificate evidencing payment of any withholding taxes hereunder and shall
reasonably assist the Assignor to obtain the benefit of any applicable tax treaty relief.

 

19.3 The Assignor
and Assignee agree that for the purposes of this Agreement, where the Assignor makes a taxable supply under or in connection with
this Agreement, the GST on the supply will be payable by the Assignee pursuant to the reverse charge provisions in section
83-5 of the GST Act.

 

19.4 Terms
used in this clause that are defined in the GST Act have the meanings given to them in that Act.

 

		20.	Giving a notice

 

20.1 A notice by a party must be
in writing and must be given to each other party.

 

20.2 A notice may be given to a
party and is treated as given to a party in any of these ways:

 

		(a)	on delivery, when delivered by hand to the party;

 

		(b)	48 hours after posting, when sent by prepaid mail or document exchange to the address of the party:

 

		(c)	when the facsimile machine confirms transmission, when sent by facsimile communication to the facsimile number of the party.

 

20.3 A notice
given on a day which is not a Business Day is treated as given on the next Business Day.

 

		21.	Term of Obligations in clause 4.1

 

21.1 Subject
to Clause 21.2, this Agreement (including the obligations of the Assignee pursuant to clause 4.1 hereof) shall terminate on the
expiry date of the last Patent to expire.

 

21.2 The obligations
stipulated in Clause 11, and the effect of all and any warranties and/or indemnities given under this Agreement shall survive,
and shall not merge on, such termination.

 

    	 

    	-17-

    

 

		22.	Public Announcements

 

The Parties shall agree the final
content of a joint press release (in English) announcing the execution of this Agreement.

 

		23.	Counterparts

 

This Agreement may be executed
in any number of counterparts and all such counterparts taken together will be deemed to constitute one instrument.

 

		24.	Transfer or Assignment of this Agreement

 

The Assignee may transfer or
assign this Agreement to any third party without consent from the Assignor, provided that

		a)	the Assignee shall provide the Assignor with a copy of a draft assignment agreement prior to execution
thereof,

		b)	said third party enters into an agreement with the Assignee assuming all the obligations of the
Assignee hereunder including the terms and conditions set forth in clause (d) of the DIC Acknowledgement: and

		c)	the Assignee continues to be liable to the Assignor hereunder for all liabilities incurred hereunder
to the date of the assignment of the said third party.

 

		25.	Exchange

 

25.1 An exchange
of original, copies or scanned counterparts of this Agreement, physically, by facsimile or by email, shall constitute a valid exchange
of counterpart Agreements.

 

25.2 In the
case of an exchange by facsimile or email, each party agrees to provide the other party with the original signed counterpart within
14 days of such exchange.

 

The rest of this page is intentionally
left blank

  

    	 

    	 

    

 

	EXECUTED as a Agreement	 	 
	 	 	 
	EXECUTED by ACTIVUS PHARMA CO., LTD,	)	 
	a Japanese Company (No.                      ), in 	)	 
	accordance with its constituent documents	)	 
	 	 	 
	 	 	 
	Signature of Director	 	Signature of Director/Secretary
	 	 	 
	YASUO AOKI	 	 
	Name of Director	 	Name of Director/Secretary
	 	 	 
	EXECUTED by MARIPOSA HEALTH PTY LTD	)	 
	(ACN 134 154 680) in accordance with the	)	 
	Corporations Act	)	 
	 	 	 
	 	 	 
	Signature of Director	 	Signature of Director/Secretary
	 	 	 
	PHILLIP COMANS	 	KEVIN LYNN
	Name of Director	 	Name of Director/SecretaryExhibit 10.3

 

Share
Sale and Purchase Agreement

 

Bioxyne Limited 

 

and

 

Mariposa Health Limited

 

and

 

Hunter Immunology Pty Limited

 

HWC
BSWORTH

LAWYERS

 

Level 14, Australia Square

264-278 George Street

SYDNEY NSW 2000 DX

129 SYDNEY

ABN 37 246 549 189

Tel:      (02)
9334 8555

Fax:      1300
369 656

 

www.hwiebsworth.corn.au

Ref: GH:US:297783

 

    	 

    	 

    

 

Table of
Contents

 

	1.	Definitions and
    interpretation	5
	 	 	 	 
	 	1.1	Definitions	5
	 	 	 	 
	 	1.2	Interpretation	7
	 	 	 	 
	 	1.3	Business Day	8
	 	 	 	 
	2.	Conditions precedent	8
	 	 	 	 
	 	2.1	Conditions	8
	 	 	 	 
	 	2.2	Cut-off date	8
	 	 	 	 
	 	2.3	Best endeavours	9
	 	 	 	 
	 	2.4	Amendment and waiver	9
	 	 	 	 
	 	2.5	Rights after termination	9
	 	 	 	 
	3.	Sale Shares	9
	 	 	 	 
	 	3.1	Sale and Purchase	9
	 	 	 	 
	 	3.2	All of the Sale Shares	9
	 	 	 	 
	 	3.3	Title to the Sale Shares	9
	 	 	 	 
	4.	Deposit	9
	 	 	 
	5.	Purchase Price	10
	 	 	 	 
	 	5.1	Purchase Price	10
	 	 	 	 
	 	5.2	No embarrassment	10
	 	 	 	 
	 	5.3	Method of payment	11
	 	 	 	 
	6.	Completion	11
	 	 	 	 
	 	6.1	Completion Date	11
	 	 	 	 
	 	6.2	Vendor's obligations	11
	 	 	 	 
	 	6.3	Purchasers obligations	12
	 	 	 	 
	 	6.4	Company's obligations	13
	 	 	 	 
	 	6.5	Conditions of Completion	13
	 	 	 	 
	7.	Warranties	13
	 	 	 	 
	 	7.1	Mutual representations and warranties	13
	 	 	 	 
	 	7.2	Vendor's Warranties	14
	 	 	 	 
	 	7.3	Purchaser warranties	14
	 	 	 	 
	 	7.4	independent warranties	14
	 	 	 	 
		7.5	Limitation on Claims for Breach
    of Warranty	14
	 	 	 	 
	8.	Post-Completion
    repayment of R&D expenses	14
	 	 	 	 
	 	8.1	R&D expenses to be repaid
    as and when received	14
	 	 	 	 
		8.2	Purchaser to procure lodgement
    of claim and payment of funds received	14
	 	 	 	 
	 	8.3	Right of inspection	15
	 	 	 	 
	9.	Exclusivity	15
	 	 	 	 
	 	9.1	No-talk restriction	15
	 	 	 	 
	 	9.2	Exception to no-talk	15
	 	 	 	 
	 	9.3	No-shop restriction	15

 

    	 

    	 

    

 

	10.	Publicity and confidentiality	15
	 	 	 
	 	10.1	Announcements	15
	 	 	 	 
	 	10.2	Publicity	16
	 	 	 	 
	 	10.3	Confidentiality	16
	 	 	 	 
	11.	Notices	16
	 	 	 
	 	11.1	Form of notice	16
	 	 	 	 
	 	11.2	Receipt	17
	 	 	 	 
	 	11.3	Address for notices	17
	 	 	 	 
	12.	General	17
	 	 	 
	 	12.1	Entire agreement	17
	 	 	 	 
	 	12.2	Assignment	17
	 	 	 	 
	 	12.3	Variation	18
	 	 	 	 
	 	12.4	Costs and expenses	18
	 	 	 	 
	 	12.5	Waiver	18
	 	 	 	 
	 	12.6	Severance	18
	 	 	 	 
	 	12.7	Counterparts	18
	 	 	 	 
	
	12.8	Further assurances	19
	 	 	 	 
	 	12.9	Governing law and jurisdiction	19

 

    	 

    	 

    

 

Share
Sale and Purchase Agreement

 

	Date

         

         

        Parties
        

         
	 

        24 February 2014

         

         

        Bioxyne Limited ACN 084
        464 193 of Suite 404,
        25 Lime Street, Sydney NSW 2000

        (Vendor)

         

        Mariposa Health Limited
        ACN 134 154 680 of Suite 6, 61 Avalon Parade, Avalon Beach NSW 2107

         

        (Purchaser)

         

        Hunter Immunology Pty
        Limited ACN 106 556 094 of ci- Traverse Accountants, Suite 404, 25 Lime Street, Sydney NSW 2000

         

        (Company)

 

Recitals

 

		A.	The
                                         Vendor is the registered holder of the Sale Shares.

 

		B.	The Vendor
                                         is an ASX listed public company which has two operating business units:

 

		(a)	a
                                         sales and distribution business involving the marketing and distribution of probiotics
                                         and other bio-pharmaceuticals for human consumption; and

 

		(b)	a
                                         biotechnology business involving the development of bio-molecular technology for commercial
                                         applications in consumer health, functional foods and pharmaceutical products including
                                         the HI-164 Oral Vaccine.

 

		C.	The Company
                                         is the holder of all intellectual property rights and chemicals and biological materials
                                         in relation to the Hl-164 Oral Vaccine.

 

		D.	The
                                         Purchaser operates a pharmaceuticals development business that holds certain Chronic
                                         Obstructive Pulmonary Disease (COPE)) technologies
                                         and the Purchaser wishes to augment its COPD technologies with the Hl-164 Oral Vaccine.

 

		E.	The Vendor
                                         wishes to sell to the Purchaser and the Purchaser wishes to purchase the Sale Shares
                                         on the terms and conditions set out in this Agreement.

 

    	4

    	 

    

 

	Share Sale and Purchase Agreement 	HWL Ebsworth

 

 The parties agree, in consideration
of, among other things, the mutual promises contained in this Agreement as follows:

 

		1.	Definitions
                                         and interpretation

 

		1.1	Definitions

 

In this Agreement, unless
the context requires otherwise:

 

Accounts
means the accounts of the Company as at and for the six month period ended 31 December 2013;

 

ASIC
means the Australian Securities and Investments Commission;

 

ASX
means ASX Limited ACN 008 624 691 or the securities exchange market operated by the ASX,
as the context requires;

 

ASX
Listing Rules means the official listing rules issued and enforced by the ASX as amended
from time to time;

 

Business
Day means a day on which banks are open for business in the State of New South Wales, Australia,
excluding a Saturday, Sunday or public holiday;

 

Claim
means any allegation, debt, cause of action, Liability, claim, proceeding, suit or demand
of any nature howsoever arising and whether present or future, fixed or unascertained, actual or contingent, whether at law, in
equity, under statute or otherwise;

 

Completion
means the time at which the transfer of the Sale Shares is completed, the issue and allotment
of the Consideration Shares occurs and the other steps required under clause 6 are performed;

 

Completion
Date means 24 February 2014 or such other date as the parties agree in writing;

 

Consideration
Shares means 1,969,697 MHL Shares issued or to be issued at the Issue Price under clause
5.1(a)(iv) representing approximately 5% of the fully diluted equity in the issued capital of the Purchaser;

 

Constitution
means the constitution of the Company; Corporations
Act means Corporations Act 2001 (Cth); Deferred
Consideration means $1,000,000;

 

Deposit
means $17,500;

 

Duty
means any stamp, transaction or registration duty or other similar charge imposed by any
Government Agency and includes, without limitation, any interest, fine, penalty, charge or other amount imposed in respect of
the above but excludes any tax;

 

Encumbrance
means any:

 

		(a)	security
                                         for the payment of money or performance of obligations, including a mortgage, charge,
                                         lien, pledge, trust, power or title retention or flawed deposit arrangement and any "security
                                         interest" as defined in section 12(1) or 12(2) of the PPSA; or

 

		(b)	any
                                         "security interest" as defined in section 12(3) of the PPSA; or

 

    	5

    	 

    

 

	Share Sale and Purchase Agreement 	HWL Ebsworth

 

		(c)	right,
                                         interest or arrangement which has the effect of giving another person a preference, priority
                                         or advantage over creditors including any right of set-off; or

 

		(d)	right
                                         that a person (other than the owner) has to remove something from land (known as a profit
                                         a prendre), easement, public right of way, restrictive or positive covenant, lease, or
                                         licence to use or occupy; or

 

		(e)	third
                                         party right or interest or any right arising as a consequence of the enforcement of a
                                         judgment,

 

or any agreement to create
any of them or allow them to exist;

 

Exclusivity
Period means the period from and including the date of the Term Sheet and ending 120 days from the date of the Term Sheet
being 30 March 2014;

 

Government
Agency means any government, governmental, semi-governmental, administrative, fiscal, judicial or regulatory body, court,
department, commission, authority, tribunal, agency or entity in any relevant jurisdiction;

 

HI-164
Oral Vaccine means the Company's oral vaccine (proposed to be developed) which uses the application of mucosal immunology
to treat common human diseases and which works by controlling bacterial infections of airways damaged by toxins and which is supported
by the Patents;

 

Immediately
Available Funds means cash, bank cheque or such other method agreed by the parties;

 

initial Purchase Price
means $157,500;

 

Intellectual
Property means all intellectual property rights including current and future registered and unregistered rights in respect
of copyright, designs, circuit layouts, trade marks, trade secrets, know-how, confidential information, patents (including the
Patents), invention and discoveries and all other intellectual property as defined in Article 2 of the Convention Establishing
the World Intellectual Property Organisation 1967 including as expressed in all reports, clinical trial documents and correspondence
relating to the HI-164 Oral Vaccine;

Intellectual Property
Rights means any right or interest in the Intellectual Property; issue Price means 16,5 cents per MHL Share;

 

Liability
means any debt or other monetary liability or penalty, fine or payment or any liabilities (whether actual, contingent or prospective),
losses, damages, costs and expenses of whatsoever nature or description including without limitation, any loans;

 

Lonza
Debt means the debt in the approximate amount of $60,000 owing to Lonza Sales Ltd by the Company, a copy of the tax invoice
is set out in Annexure A;

 

MHL Share means
a fully paid ordinary share in the capital of the Purchaser;

 

Official
List means the official list of entities that the ASX has admitted and not removed from listing;

 

Official
Quotation or Officially Quoted means officially quoted on the ASX;

 

Ordinary
Shares means Shares having the rights and being subject to the restrictions of ordinary shares contained in the Constitution;

 

PPSA means the
Personal Property Securities Act 2009 (Cth);

 

    	6

    	 

    

 

	Share Sale and Purchase Agreement 	HWL Ebsworth

 

Patents
means the patents listed in Schedule 2;

 

Purchase Price has
the meaning given to that term in clause 5.1(a);

 

Royalty
Agreement means the royalty agreement between the Vendor and the Purchaser dated on or about the date of Completion in relation
to the HI-164 Oral Vaccine set out in Annexure 13;

 

Sale
Shares means 393,982,080 D fully paid ordinary Shares representing all of the issued capital in the Company;

 

Shareholder means
a holder from time to time of any Shares;

 

Shares
means all of the shares and other equity securities (including options over shares) in the capital of the Company having the
rights and being subject to the restrictions contained in the Constitution, and where the context allows, includes, without limitation,
unissued shares; and

 

Term
Sheet means the Term Sheet between the Vendor and the Purchaser dated

30 November 2013 in relation
to the transaction underlying the Transaction Documents;

Third Party Proposal
has the meaning given to that term in clause 9.1; Transaction Documents means the:

 

		(a)	this
                                         Agreement; and

 

		(b)	the
                                         Royalty Agreement;

 

Vendor
Warranties means the representations and warranties made by the Vendor and set out in the Schedule; and

 

VWAP
means the daily volume weighted average market price of shares in the Purchaser transacted on the ASX's trading platform.

 

		1.2	interpretation

 

In this Agreement, unless
the context requires otherwise:

 

		(a)	headings
                                         and italicised, highlighted or bold type do not affect the interpretation of this Agreement;

 

		(b)	the
                                         singular includes the plural and the plural includes the singular;

 

		(c)	a
                                         gender includes all other genders;

 

		(d)	other
                                         parts of speech and grammatical forms of a word or phrase defined in this the have a
                                         corresponding meaning;

 

		(e)	a
                                         reference to a "person" includes any individual, firm, company, partnership,
                                         joint venture, an unincorporated body or association, trust, corporation or other body
                                         corporate and any Government Agency (whether or not having a separate legal personality);

 

		(f)	a
                                         reference to any thing (including any right) includes a part of that thing, but nothing
                                         in this clause 1.2(f) implies that performance of part of an obligation constitutes performance
                                         of the obligation;

 

    	7

    	 

    

 

	Share Sale and Purchase Agreement 	HWL Ebsworth

 

		(g)	a
                                         reference to a clause, party, annexure, exhibit or schedule is a reference to a clause
                                         of, and a party, annexure, exhibit and schedule to, this Agreement and a reference to
                                         this Agreement includes any clause, annexure, exhibit and schedule;

 

		(h)	a
                                         reference to a document (including this Agreement) includes all amendments or supplements
                                         to, or replacements or novations of, that document;

 

		(i)	a
                                         reference to a party to any document includes that party's successors and permitted assigns;

 

		(i)	a
                                         reference to time is to Sydney time;

 

		(k)	the
                                         word person means
                                         a natural person and any association, body or entity whether incorporated or not;

 

		(1)	where
                                         any word or phrase is defined, any other part of speech or other grammatical form of
                                         that word or phrase has a cognate meaning;

 

		(m)	a
                                         reference to "S", "A$", "dollars" or "Dollars"
                                         is a reference to the lawful currency of the Commonwealth of Australia;

 

		(n)	a
                                         covenant or agreement on the part of two or more persons binds them jointly and severally;

 

		(a)	no
                                         rule of construction applies to the disadvantage of a party because this Agreement is
                                         prepared by (or on behalf of) that party; and

 

		(p)	a
                                         reference to any thing is a reference to the whole and each part of it.

 

		1.3	Business
                                         Day

 

If anything under this
Agreement is required to be done by or on a day that is not a Business Day that thing must be done by or on the next Business
Day.

 

		2.	Conditions
                                         precedent

 

		2.1	Conditions

 

Completion
of this Agreement will not proceed unless and until each of the following conditions precedent have been fulfilled:

 

		(a)	Board
                                         approval: the board of directors
                                         of the:

 

		(I)	Vendor
                                         approving the entry into each of the Transaction Documents; and

 

		(ii)	Purchaser
                                         approving the entry into each of the Transaction Documents;

 

		(b)	Excluded
                                         assets: all intellectual properties
                                         or other technologies held in the Company that are not relevant to the HI-164 Oral Vaccine
                                         to be transferred from the Company to the Vendor or a nominated subsidiary of the Vendor.

 

		2.2	Cut-off
                                         date

 

If
any conditions precedent set out in clause 2.1 cannot be satisfied or is not satisfied or waived on or before 28 February 2014
or such other date as agreed by the parties in writing, each party may, by not less than two Business Days' written notice to
the other parties, terminate this Agreement.

 

    	8

    	 

    

 

	Share Sale and Purchase Agreement 	HWL Ebsworth

 

		2.3	Best
                                         endeavours

 

Each
party must use its best endeavours to satisfy the conditions precedent in clauses 2.1(a) and 2.1(b).

 

		2.4	Amendment
                                         and waiver

 

The
conditions precedent may only be amended with the agreement of the parties or waived or deferred by the Vendor.

 

		2.5	Rights
                                         after termination

 

		(a)	If
                                         this Agreement is terminated pursuant to clause 2.2 then, in addition to any other rights,
                                         powers or remedies under law:

 

		(i)	subject
                                         to the provisions of clause 2.5(b), this Agreement will be of no further effect and no
                                         party will be liable to any other party except in respect of any breach of this Agreement
                                         occurring before that termination, and each party is released from its obligations to
                                         perform under this Agreement; and

 

		(ii)	each
                                         party retains the rights it has against any other party concerning a past breach of this
                                         Agreement

 

		(b)	Clause
                                         2.5(a) does not apply to a party's obligations of confidentiality as set out in clause
                                         10.3.

 

		3.	Sale
                                         Shares

 

		3.1	Sale
                                         and Purchase

 

The
Vendor agrees to sell the Sale Shares to the Purchaser, and the Purchaser agrees to buy the Sale Shares from the Vendor:

 

		(a)	for
                                         the Purchase Price;

 

		(b)	free
                                         from all Encumbrances; and

 

		(c)	with
                                         effect from Completion, on the terms of this Agreement.

 

		3.2	All
                                         of the Sale Shares

 

The
Parties agree that the sale and purchase of all the Sale Shares will be completed simultaneously.

 

		3.3	Title
                                         to the Sale Shares

 

Title to, property in
and risk of the Sale Shares:

 

		(a)	until
                                         Completion, remains solely with the Vendor; and

 

		(b)	passes
                                         to the Purchaser absolutely on and from Completion.

 

		4.	Deposit

 

		(a)	The
                                         Vendor acknowledges receipt of payment of the Deposit from the Purchaser in
                                         Immediately Available Funds on the date of the Term Sheet

 

    	9

    	 

    

 

	Share Sale and Purchase Agreement 	HWL Ebsworth

 

		(b)	In
                                         the event Completion does not occur due to lack of approval by the board of the Purchaser,
                                         the Deposit will be retained by the Vendor and the Purchaser must reimburse to the Vendor
                                         the amount equal to all of the Vendor's transaction costs of up to $20,000 (including
                                         consulting fees).

 

		(c)	In
                                         the event Completion does not occur due to lack of approval by the board of the Vendor,
                                         the Vendor must reimburse to the Purchaser the amount equal to all of the Purchaser's
                                         transaction costs of up to $20,000 (including consulting fees).

 

		5.	Purchase
                                         Price

 

		5.1	Purchase
                                         Price

 

		(a)	The
                                         purchase price for the Sale Shares (Purchase Price)
                                         is the aggregate of:

 

		(i)	the
                                         Deposit;

 

		(ii)	the
                                         Initial Purchase Price, payable at Completion;

 

		(iii)	the
                                         assumption of the Lonza Debt by the Purchaser at Completion;

 

		(iv)	$325,000,
                                         which will be satisfied by the issue of the Consideration Shares to the Vendor at the
                                         Issue Price at Completion; and

 

		(v)	the
                                         Deferred Consideration, which wilt, at the election of the Purchaser, be satisfied by,
                                         either:

 

		(A)	the
                                         issue of MHL Shares to the Vendor; or

 

		(B)	cash,

 

following
commercialisation success achieved within five years from the Completion Date and subject to the achievement of the following
milestones:

 

		(C)	the
                                         HI-164 Oral Vaccine completes a successful Phase 2 clinical trial (statistically significant,
                                         p:Q.05, beneficial results with at least 65% of primary end-points) or any other mutually
                                         agreed commercial transaction (e.g. licence, co-development with a third party) (Milestone
                                         A); and

 

		(D)	the
                                         market capitalisation or value of the Purchaser exceeding $100,000,000, and the 111-164
                                         Oral Vaccine project continues to be in development by the Purchaser,

 

Where
the Purchaser elects to pay the Deferred Consideration to the Vendor in equity, the number of shares to be issued will be calculated
on the 30 day VWAP of the Purchaser on the date prior to the date Milestone A was announced on the ASX.

 

		(b)	The
                                         Consideration Shares must be issued by the Purchaser free from any Encumbrance and so
                                         that on issue they rank equally in all respects with all other MI-IL Shares on issue.

 

		5.2	No
                                         embarrassment

 

		(a)	Where
                                         the Consideration Shares have been acquired by the Vendor in accordance with
                                         clause 5.1(a)(iv) and the Purchaser is admitted to the Official List resulting in the
                                         MHL Shares being Officially Quoted at a price such that the Consideration Shares are
                                         worth less than $325,000, the number of Consideration Shares will be increased to reflect
                                         the value of $325,000, such number of additional new issuable MHL Shares to be calculated
                                         by reference to the Officially Quoted price per MHL Share when MHL is admitted to the
                                         official list of ASX.

 

    	10

    	 

    

  

	Share Sale and Purchase Agreement 	HWL Ebsworth

 

		(b)	For
                                         the avoidance of doubt, where the MHL Shares are Officially Quoted at a price greater
                                         than the Issue Price (and there has been no share capital reconstruction such as a consolidation),
                                         there will be no adjustment to the number of Consideration Shares already issued to the
                                         Vendor.

 

		5.3	Method
                                         of payment

 

Each payment to be made
to the Vendors under this Agreement must be made by Immediately Available Funds.

 

		6.	Completion

 

		6.1	Completion
                                         Date

 

Completion must be effected
on the Completion Date at HWL Ebsworth (Sydney) at 12:00 noon (or at any other place or time agreed between the parties).

 

		6.2	Vendor's
                                         obligations

 

On Completion, the Vendor
must:

 

		(a)	deliver
                                         or cause to be delivered or provide to the Purchaser:

 

		(i)	the
                                         Royalty Agreement duly executed by the Vendor,

 

		(ii)	duly
                                         executed transfers in favour of the Purchaser in registrable form and share certificates
                                         in respect of all of the Sale Shares;

 

		(iii)	all
                                         existing letters in the Company's possession from inventors as proof of unencumbered
                                         ownership of the Company's patents or patents pending;

 

		(iv)	the
                                         certificate of incorporation, common seal (where applicable), all statutory, minute and
                                         other record books, share certificate books of the Company and all unused share certificate
                                         forms;

 

		(v)	all
                                         ledgers, journals and books of account of the Company;

 

		(vi)	duly
                                         executed written resignations of:

 

		(A)	Anthony
                                         Peng Ho as director of the Company;

 

		(B)	Jarrod
                                         Travers White as the secretary and public officer of the Company;

 

		(vii)	any
                                         other document which the Purchaser acting reasonably requires to obtain good title to
                                         the Sale Shares and to enable the Purchaser to cause the registration of the Sale Shares
                                         in the name of the Purchaser including, without limitation, any power of attorney under
                                         which the document delivered under this Agreement has been signed;

 

		(viii)	unencumbered
                                         reasonable access to all technical and scientific documents owned by the Company that
                                         relate to Hl-164, including reports, original documents, and submissions to regulatory
                                         authorities;

 

    	11

    	 

    

 

	Share Sale and Purchase Agreement 	HWL Ebsworth

 

		(ix)	unencumbered
                                         reasonable access to chemicals and biological materials
                                         belonging to the Company;

 

		(b)	procure
                                         that a meeting of the directors of the Company is held at which those directors
                                         will:

 

		(i)	approve
                                         the entering into and performance of the Royalty Agreement;

 

		(ii)	approve
                                         the transfers of the Sale Shares to the Purchaser;

 

		(iii)	approve
                                         (subject to payment of stamp duty) the registration of the transfers of the Sale Shares
                                         to the Purchaser;

 

		(iv)	approve
                                         the cancellation of the existing share certificate for the Sale Shares;

 

		(v)	approve
                                         the issue of a new share certificate to the Purchaser,

 

		(vi)	approve
                                         a change of registered office and principal place of business to Unit 6, 61 Avalon Parade,
                                         Avalon NSW 2107;

 

		(vii)	approve
                                         the resignations of:

 

		(A)	Anthony
                                         Peng Ho as the director of the Company;

 

		(B)	Jarrod
                                         Travers White as secretary and public officer of the Company;

 

		(viii)	approve
                                         the appointments of:

 

		(A)	Kevin
                                         Martin Lynn as director of the Company;

 

		(B)	Robert
                                         Edward Lees as secretary and public officer of the Company;

 

		(c)	confer
                                         on the Purchaser title to the Sale Shares and do all things reasonably necessary to ensure
                                         that all licences and assets currently held and/or owned by the Company remain so held
                                         and owned after Completion; and

 

		(d)	deliver
                                         to the Company the Royalty Agreement duly executed by the Vendor.

 

		6.3	Purchaser's
                                         obligations

 

On Completion, the Purchaser
must:

 

		(a)	deliver
                                         to the Vendor and the Company the Royalty Agreement duly executed by the Purchaser;

 

		(b)	issue
                                         the Consideration Shares to the Vendor;

 

		(c)	deliver
                                         to the Vendor a share certificate stating that the Vendor is the holder of the Consideration
                                         Shares;

 

		(d)	enter
                                         the Vendor in the register of members of the Purchaser;

 

		(e)	deliver
                                         to the Company duly executed consents to act of:

 

		(i)	Kevin
                                         Martin Lynn as director of the Company;

 

		(ii)	Robert
                                         Edward Lees as secretary and public officer of the Company; and

 

		(f)	pay
                                         the Initial Purchase Price in Immediately Available Funds.

 

    	12

    	 

    

 

	Share Sale and Purchase Agreement 	HWL Ebsworth

 

		6.4	Company's
                                         obligations

 

On Completion, the Company
must:

 

		(a)	deliver
                                         to the Purchaser and the Vendor the Royalty Agreement duly executed by the Company;

 

		(b)	subject
                                         to payment of any duty on the transfer of the Sale Shares:

 

		(i)	enter
                                         the name of the Purchaser in the register of members of the Company as the holder of
                                         the Sale Shares;

 

		(ii)	deliver
                                         or cause to be delivered to the Purchaser a duly executed share certificate in respect
                                         of the Sale Shares; and

 

		(iii)	take
                                         all other steps required under the Constitution and the Corporations Act to constitute
                                         and evidence the Purchaser as the holder of the Sale Shares.

 

		6.5	Conditions
                                         of Completion

 

		(a)	Completion
                                         is conditional on both the Purchaser and the Vendor complying with all of their obligations
                                         under this clause 6.

 

		(b)	If
                                         either the Vendor or the Purchaser fails to fully comply with its obligations under this
                                         clause 6 and the parties do not complete this Agreement then:

 

each
party must return to the other all documents delivered to it under this clause 6;

 

each
party must repay to the other all payments received by it under this clause 6;

 

		i)	each
                                         party must do everything reasonably required by the other party to reverse any action
                                         taken under this clause 6;

 

without prejudice to any
other rights any party may have in respect of that failure.

 

		7.	Warranties

 

		7.1	Mutual
                                         representations and warranties

 

Each of the parties represents
and warrants that;

 

		(a)	it
                                         has the power to enter into this Agreement and has taken all corporate and other actions
                                         necessary to authorise the execution, delivery and performance of this Agreement;

 

		(b)	this
                                         Agreement constitutes a valid, legally binding obligation on it;

 

		(c)	the
                                         execution, delivery and performance of this Agreement will not violate any provision
                                         of its constitution or any provision of any document or agreement to which it is a party
                                         or which is binding upon it or any of its assets; and

 

		(d)	all
                                         authorisations, consents and approvals (if any) required from any Government Agency in
                                         connection with the transactions contemplated by this Agreement have been obtained and
                                         in the case of the Vendor no approval or waiver is required under the ASX Listing Rules.

 

    	13

    	 

    

 

	Share Sale and Purchase Agreement 	HWL Ebsworth

 

		72	Vendor's
                                         Warranties

 

The Vendor represents
and warrants to the Purchaser that the Vendor Warranties are accurate as at the date of this Agreement and the actual Completion
Date in relation to the facts then subsisting.

 

		7.3	Purchaser
                                         warranties

 

At Completion, the Purchaser
represents and warrants as at the date of this Agreement and the actual Completion Date in relation to the facts then subsisting
that:

 

		(a)	it
                                         is able to issue and allot the Consideration Shares without the consent of any other
                                         person and free of any Encumbrance, pre-emptive rights or rights of first refusal; and

 

		(b)	it
                                         has taken all necessary action to authorise the execution, delivery and performance of
                                         this Agreement in accordance with its terms.

 

		7.4	Independent
                                         warranties

 

Each of the warranties
is to be construed independently of the others and is not limited by reference to any other warranty.

 

		7.5	Limitation
                                         on Claims for Breach of Warranty

 

The Purchaser's right
to claim for breach of the Vendor Warranties is limited as follows:

 

		(a)	by
                                         the actual knowledge, as at the date of this Agreement, of the Purchaser (including the
                                         Purchaser's directors);

 

		(b)	the
                                         Purchaser must give written notice to the Vendor of the general nature of the claim in
                                         question within two years after the Completion Date;

 

		(c)	the
                                         aggregate amount of claims in respect of all breaches must exceed 10% of the Initial
                                         Purchase Price, in which case the Purchaser may recover all amounts claimed and not just
                                         the excess over 10% of the Initial Purchase Price; and

 

		(d)	the
                                         maximum aggregate amount which the Purchaser may recover from the Vendor in respect of
                                         all claims (exclusive of interest and the costs and expenses of making claims) is the
                                         Initial Purchase Price.

 

		8.	Post-Completion
                                         repayment of R&D expenses

 

		8.1	R&D
                                         expenses to be repaid as and when received

 

The
parties agree that in relation to any tax credit, benefit or other monies received from the Australian Tax Office or other Government
Agency by the Company after the Completion Date in respect of research and development expenditure incurred by the Company prior
to the Completion Date will as and when received by the Company be due and payable by the Company to the Vendor and the Purchaser
in accordance with clause 8.2(b) in the following proportions:

 

		(a)	75%
                                         - Vendor; and

 

		(b)	25%
                                         - Purchaser.

 

		8.2	Purchaser
                                         to procure lodgement of claim and payment of funds received

 

The Purchaser must procure
that the Company complies with clause 8.1 and, in particular:

 

    	14

    	 

    

 

	Share Sale and Purchase Agreement 	HWL Ebsworth

 

		(a)	use
                                         reasonable endeavours to lodge all reasonably claimable research and development expenditure
                                         claims on or before 31 August 2014 in respect of the period prior to the Completion Date;
                                         and

 

		(b)	must
                                         procure that the Company pays to the Vendor and Purchaser any monies due and payable
                                         under clause 8.1 within 5 Business Days of the Company receiving such monies.

 

		8.3	Right
                                         of inspection

 

The
Vendor may request all reasonable access to either or both of the Purchaser's and the Company's records, premises and personnel
to verify to its own reasonable satisfaction whether the Company and the Purchaser have complied with this clause 8.

 

		9.	Exclusivity

 

		9.1	No-talk
                                         restriction

 

The
Vendor (and/or any of its directors and officers) undertakes to the Purchaser that it will not negotiate or deal with any other
person or entity relating to an investment in, or acquisition of, all or any part of the Company or the Sales Shares (Third
Party Proposal) other than with the Purchaser or with the prior written approval of the Purchaser during the Exclusivity Period.

 

		9.2	Exception
                                         to no-talk

 

The
restrictions in clause 9.1 do not apply to the extent that they restrict the Company from taking or refusing to take any action
with respect to a bona fide proposal in relation to a Third Party Proposal in circumstances where the directors of the Company
must cause the Company to undertake any act or acts with respect to the proposed Third Party Proposal which would otherwise be
prohibited by the terms of this clause 8 in order to discharge properly their fiduciary or statutory duties or to avoid contravention
of the law.

 

		9.3	No-shop
                                         restriction

 

During
the Exclusivity Period, the Purchaser (and/or any of its officers, directors, contractors or employees) undertakes not to directly
or indirectly solicit, invite, facilitate, encourage or initiate any enquiries, negotiations or discussions, or communicate any
intention to do any of these things, with a view to obtaining any expression of interest, offer or proposal from any other person
in relation to seeking alternative assets to acquire to augment its COPD technologies.

 

		10.	Publicity
                                         and confidentiality

 

		10.1	Announcements

 

in
consideration of each party entering into and performing their respective obligations under, and in accordance with the provisions
of, this Agreement, each party agrees, except as required by law or by the ASX Listing Rules (if applicable) that:

 

		(a)	the
                                         terms of this Agreement are to be kept confidential and released to persons who are not
                                         a party to this document (other than the professional advisers to the parties) only by
                                         the prior mutual written consent of the parties; and

 

		(b)	no
                                         party shall make any press release in relation to this Agreement without the prior consent
                                         in writing of the other party.

 

    	15

    	 

    

 

	Share Sale and Purchase Agreement 	HWL Ebsworth

 

		10.2	Publicity

 

No
public announcement or communication relating to the negotiations of the parties or the subject matter or terms of this Agreement
is to be made or authorised by or on behalf of any party without the prior written approval of the other party.

 

		10.3	Confidentiality

 

Each
party agrees with the other party that all information in relation to the other party's business including, without limitation,
any trade secrets, operations, know-how, or any information concerning the organisation, management and finance of the other party
or in relation to the Vendor or in relation to any associate or related body corporate of the Vendor, which is exchanged between
them during the negotiations prior to the Completion Date or in the course of any party performing its duties or obligations under
the provisions of this Agreement, is confidential and shall not be disclosed, divulged or otherwise placed at the disposal of
any person not being a party to this Agreement or a related body corporate except:

 

		(a)	to
                                         employees, legal advisers, auditors and other consultants requiring the information for
                                         the purpose of this Agreement;

 

		(b)	with
                                         the consent of the party who supplied the information;

 

		(c)	if
                                         the information is, prior to the Completion Date, lawfully in the possession of the recipient
                                         of the information through sources other than the party who supplied the information;

 

		(d)	if
                                         required by law or the ASX;

 

		(e)	if
                                         strictly and necessarily required in connection with legal proceedings; and

 

if
the information is or becomes generally and publicly available other than through the default of a party who divulges the information.

 

		11.	Notices

 

		11.1	Form
                                         of notice

 

All
notices, requests, demands, consents, approvals, agreements or other communications (notices) to or by a party given for
the purposes of Agreement must be:

 

		(a)	in
                                         writing;

 

		(b)	signed
                                         by the party giving notice or a person duly authorised by that party or, where transmitted
                                         by e-mail, sent by the party giving notice or a person duly authorised by that party;

 

		(c)	directed
                                         to the recipient's address (as specified in clause 11.3 or as varied by any notice);
                                         and

 

		(d)	hand
                                         delivered, sent by prepaid post or transmitted by email or facsimile to that address,

 

and
will be taken to be duly given or made (in the case of delivery in person or by post or email or facsimile transmission) when
delivered, received or left at the address of the recipient shown in this Agreement or to any other address which it may have
notified the sender.

 

    	16

    	 

    

 

	Share Sale and Purchase Agreement 	HWL Ebsworth

 

		11.2	Receipt

 

A notice given in accordance
with this clause is taken as having been given and received:

 

		(a)	if
                                         hand delivered at or before 4.00 pm on a Business Day, on delivery, otherwise at 9.30
                                         am on the next Business Day;

 

		(b)	if
                                         sent by prepaid post, on the seventh Business Day after the date of posting;

 

		(c)	if
                                         transmitted by e-mail, on the first Business Day after the date of transmission; or

 

		(d)	if
                                         transmitted by facsimile at or before 4.00 pm on a Business Day, at the time recorded
                                         on the transmission report indicating successful transmission of the entire notice, otherwise
                                         at 9.30 am on the next Business Day.

 

11.3 Address for notices

 

Unless varied by notice
in accordance with this clause 11.3, the parties' addresses and other details are:

 

	(a)	if to the Vendor:

 

	Address:	Suite
    404, 25 Lime Street, Sydney NSW 2000

 

	Email:	jarrod ©taccou ntants.com
    .au
	 	 
	Attention:	Jarrod White 

 

	(b)	if to the Purchaser:

 

	Address:	Suite 6, 61 Avalon Parade, Avalon
    Beach
	 	NSW 2107
	 	 
	Email:	pcomansamariposahealth.com.au 
	 	 
	Attention:	Phillip Comans

 

	(c)	if to the Company:

 

	Address: 	c/- Traverse Accountants, Suite
    404, 25 Lime Street, Sydney NSW 2000  
	 	 
	Email:	 jarrod@taccountants.com.au
	 	 
	Attention:	Jarrod White

 

		12.	General

 

		12.1	Entire
                                         agreement

 

This
Agreement states all of the express terms of the agreement between the parties in respect of its subject matter. It supersedes
all prior discussions, negotiations, understandings and agreements in respect of its subject matter.

 

		12.2	Assignment

 

No
party may assign or otherwise deal with any of its rights under this Agreement, without the prior written consent of the other
party.

 

    	17

    	 

    

 

	Share Sale and Purchase Agreement 	HWL Ebsworth

 

		12.3	Variation

 

A
variation of any term of this Agreement will be of no force or effect unless it is in writing and signed by each of the parties.

 

		12.4	Costs
                                         and expenses

 

		(a)	The
                                         Purchaser must pay any Duty in respect of the execution, delivery and performance of
                                         this Agreement and any agreement or document entered into or signed under this Agreement

 

		(b)	Subject
                                         to clause 12.4(a) and any other term of this Agreement, each party must pay its own costs
                                         and expenses in respect of the negotiation, preparation, execution, delivery and registration
                                         of this Agreement or other agreement or document described in clause 12.4(a)

 

		(c)	Any
                                         action to be taken by a party in performing its obligations under this Agreement must
                                         be taken at its own cost and expense unless otherwise provided in this Agreement

 

		12.5	Waiver

 

		(a)	A
                                         party may not rely on the words or conduct (including a delay in the exercise, a non-exercise
                                         or a partial exercise of a right) of the other party as a waiver of any right arising
                                         under or in connection with this Agreement (including a right to rely on this clause)
                                         unless the waiver is in writing and signed by the party granting the waiver.

 

		(b)	In
                                         clause 12.5(a) the term waiver is
                                         intended to include an election between rights and remedies as well as conduct which
                                         might otherwise give rise to an estoppel.

 

		(c)	A
                                         waiver is only effective in relation to the particular obligation or breach in respect
                                         of which it is given and is not to be taken as an implied waiver of any other obligation
                                         or breach or as an implied waiver of that obligation or breach in relation to any other
                                         occasion,

 

		12.6	Severance

 

		(a)	If
                                         a provision in this Agreement is wholly or partly void, illegal or unenforceable in any
                                         relevant jurisdiction that provision or part must, to that extent, be treated as deleted
                                         from this Agreement for the purposes of that jurisdiction. This does not affect the validity
                                         or enforceability of the remainder of the provision or any other provision of this Agreement.

 

		(b)	Clause
                                         12.6(a) does not apply and has no effect if severance of the provision of this Agreement
                                         in accordance with clause 12.6(a) materially affects or alters the nature or effect of
                                         the parties' obligations under this Agreement

 

		12.7	Counterparts

 

		(a)	This
                                         Agreement may be executed in any number of counterparts, each signed by one or more parties.
                                         Each counterpart when so executed is deemed to be an original and all such counterparts
                                         taken together constitute one document

 

		(b)	A
                                         party that has executed a counterpart of this Agreement may exchange that counterpart
                                         with another party by faxing it to the other party and, if that other party requests
                                         it, promptly delivering that executed counterpart by hand or post to the other party.
                                         However, the validity of this Agreement is not affected if the party who has faxed the
                                         counterpart delays in delivering or does not deliver it by hand or by post.

 

    	18

    	 

    

 

	Share Sale and Purchase Agreement 	HWL Ebsworth

 

		12.8	Further
                                         assurances

 

Each party must, at its
own expense, do all things and execute all further documents necessary to give full effect to this Agreement and the transactions
contemplated by it.

 

		12.9	Governing
                                         law and jurisdiction

 

		(a)	This
                                         Agreement is governed by and is to be construed under the laws in force in New South
                                         Wales.

 

		(b)	Each
                                         party irrevocably submits to the non-exclusive jurisdiction of the courts exercising
                                         jurisdiction in New South Wales and courts of appeal from them in respect of any proceedings
                                         arising out of or in connection with this Agreement. Each party irrevocably waives any
                                         objection to the venue of any legal process in these courts on the basis that the process
                                         has been brought in an inconvenient forum.

 

    	19

    	 

    

 

	Share Sale and Purchase Agreement 	HWL Ebsworth

 

Schedule
'I - Vendor Warranties

 

Continuous Disclosure

 

The
Vendor complies at all times with its continuous disclosure obligations under ASX Listing Rule 3.1 and section 674 of the Corporations
Act 2001 (Cth) in respect of the Company, including without limitation the Company's assets and liabilities and the Company's
Patents and Intellectual Property Rights.

 

		2.	Shares
                                         and capital

 

		2.1.	Title

 

The
Vendor is the legal and beneficial owner of the Shares which are free of all Encumbrances and other third party interests or rights.

 

		2.2.	Issue
                                         of other securities

 

The
Company is not under any obligation to issue or allot any shares or other securities and has not granted any person the right
to call for the issue or allotment of any shares or other securities of the Company at any time.

 

		3.	Status
                                         of the Company and of the Authority

 

		3.1.	Corporate
                                         existence

 

The Company:

 

		(a)	is
                                         a proprietary limited company;

 

		(b)	has
                                         the power to own its assets and carry on its business as it is now being conducted;

 

		(c)	has
                                         the capacity to sue and be sued in its own name;

 

		(d)	is
                                         not registered and is not required to be registered in any place as a recognised foreign
                                         company; and

 

		(e)	does
                                         not carry on business in any place other than Australia.

 

		3.2.	Compliance
                                         with constitution

 

The
business affairs of the Company have been conducted in accordance with the constitution of the Company.

 

		3.3.	No
                                         legal impediment

 

The execution, delivery
and performance by the Vendor of this Agreement complies with:

 

		(a)	each
                                         law, regulation, authorisation, ruling, judgement, order or decree of any Government
                                         Agency or other regulatory or legislative body;

 

		(b)	the
                                         constitution of the Vendor as applicable; and

 

    	20

    	 

    

 

	Share Sale and Purchase Agreement 	HWL Ebsworth

 

		(c)	any
                                         Encumbrance or document which is binding on the Vendor in relation to the Shares
                                         of the Company.

 

		3.4.	No
                                         breach

 

The signing and delivery
of this Agreement and the performance by the Vendor of its obligations under it complies with:

 

		(a)	any
                                         applicable law and authorisation; and

 

		(b)	any
                                         Encumbrance or document binding on the Vendor, in relation to the shares of the Company.

 

		4.	Accounts

 

The
Accounts:

 

		(a)	have
                                         been prepared consistent with the methods of accounting prescribed by the Corporations
                                         Act and the Accounting Standards as reasonably applied to a business which is the same
                                         size and complexity as that of the Company;

 

		(b)	show
                                         a true and fair view of the financial position and the assets and liabilities (including
                                         any contingent liabilities and any unusual or non-recurring items) of the Company as
                                         at 21 February 2014 and of the income, expenses and results of the operations of the
                                         Company for the financial period ending on the Accounts Date in accordance with the Accounting
                                         Standards and the Corporations Act; and

 

		(c)	the
                                         Company has no actual or contingent liabilities other than the Lonza Debt and the liabilities
                                         incurred by the Company in the ordinary course of business as listed in Annexure C.

 

Solvency

 

No
insolvency event has occurred and remains current and the Company has not gone into liquidation or passed any winding-up resolutions
nor received any deregistration notice under section 601AB or applied for deregistration under section 601AA of the Corporations
Act and there are no circumstances which could give rise to any such circumstances in respect of the Company.

 

		6.	Intellectual
                                         Property

 

All
Intellectual Property, documents, reports, biological specimens and other rights attaching to the Hl-164 Oral Vaccine are owned
by the Company.

 

		7.	Other
                                         information

 

All
information provided to the Purchaser by the Vendor and the Company in connection with the transaction contemplated by this Agreement
is true, accurate and complete in all material respects.

 

    	21

    	 

    

 

	Share Sale and Purchase Agreement 	HWL Ebsworth

 

 

 

    	22

    	 

    

 

	Share Sale and Purchase Agreement 	HWL Ebsworth

 

Executed as
an agreement

 

Executed
by Bioxyne Limited ACN 084 464 193 in
accordance with section 127(1) of the Corporations Act 2001 (Cth) by:

 

	Signature of Director	 	Signature of Director/Company
    Secretary
	 	 	 
	Full name (print)	 	Full name (print)
	 	 	 

 

Executed
by Mariposa Health Limited ACN 134 154 680 in
accordance with section 127(1) of the Corporations Act 2001 (Cth) by:

 

	Signature of Director	 	Signature of Director/Company
    Secretary
	 	 	 
	Full name (print)	 	Full name (print)

 

Executed
by Hunter Immunology Pty Limited ACN 106 556 094 in
accordance with section 127(1) of the Corporations Act 2001 (Cth) by:

 

	Signature of Director	 	Signature of Director/Company
    Secretary
	 	 	 
	Full name
    (print)	 	Full name (print)
	 	 	 

 

    	23

    	 

    

 

	Share Sale and Purchase Agreement 	HWL Ebsworth

 

Annexure A — Tax Invoice

 

	
        Loma Sees Ltd

        lituenclumstairtemetrame 36 

CH-4002 Beate, Switzerland
	 
	 	 
	
        Tei +41 81 316 81 11

        Fax 1,41 01 316 91 11
	 

 

	
        Hunter Immunology|

        Limited Suite 1005

        4 Bridge Suite

        Sydney NSW 2000

        Australien
	
        Yew order

        Hunter Immunology Ltd

        dated March 07,2012

        Oar order 0' rkierety

        3897'357

        Cur internal reference

        90683773: dated October 31,. 2012

        Olir account document

        CI-105 1 2012 4057281

 

Basel, October 31, 2012 Invoice

Nws 40572g1::64-110E's.r.-

 

	Product	 	i artlily	 	 	Price	 	 	 	 	 	Ammst In Gap	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Payment due upon completion of work at termination of Stage 1A: Activity Assay (ELISA) Transfer and Optimisation, as per Amendment 1 to the Agreement dated 15th February 2008	 	 		 	 	 		 	 	 		 	 	 		 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	1.000
                                         EA	 	 	 	42,678.00
                                         GBP	 	 	 	1
                                         EA	 	 	 	42,678.00	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total	 	 	 	 	 	 	 	 	 	 	 	 	 	 	42,678.00	 

 

	 	30 days from date of invoice net
	 	to our account no_ 75442901 (Lorca Sales Ltd} with
	 	UBS AG, London Branch, BIC: UBSWG1355
	 	IRAN: G666U85W23232075442901 CHAPS Sort
	 	Code 23-23-20 /BAGS Sort Code 60-95-30 FAST
	 	EH Sort Code B0-95-30
	 	 
	 	ATTBITION: new account for our Gi3P customers (please see above}

Reese quote the above Invoice Number in your remittance advice
	 	 
	 	E(W Slough (Incoterms 2010), at
	 	Hunter Immunology Limited Suite 1005
	 	4 Bridge Suite , AU - Sydney
	 	on October 31, 2012 ex stock United Kingdom
	 	 
	Remarks	OUT EOR1-No: 0E4-701801

 

    	24

    	 

    

 

	Share Sale and Purchase Agreement 	HWL Ebsworth

 

Annexure
B — Royalty Agreement

  

    	25

    	 

    

 

Royalty
Agreement

 

Bioxyne
Limited

 

and

 

Mariposa
Health Limited

 

and

 

Hunter
Immunology Pty Limited

 

HNC
BSWORTH

LAWYERS

 

Level
14, Australia Square

264-278 George Street SYDNEY NSW
2000 DX 129 SYDNEY ABN 37 246 549 189

Tel:    (02)
9334 8555

Fax:    1300
369 656

 

www.hwlebsworth.cormau

Ref: GB:TH:298079

 

    	 

    	 

    

 

Table
of Contents

 

	1.	Definitions and
    interpretation	0
	 	 	 	 
		1.1	Definitions	0
	 	 	 	 
	 	1.2	Interpretation	2
	 	 	 	 
		1.3	Business Day	3
	 	 	 	 
	2.	Commencement	3
	 	 	 	 
	3.	Mariposa	3
	 	 	 	 
	4.	Royalties	3
	 	 	 	 
	 	4.1	Obligation to Pay Royalties	3
	 	 	 	 
	 	4.2	Royalties	3
	 	 	 	 
	 	4.3	Combined intellectual property	4
	 	 	 	 
	 	4.4	Revenues other than cash	4
	 	 	 
	5.	Payment of Royalty	4
	 	 	 	 
	 	5.1	Notification of Royalty	4
	 	 	 	 
	 	5.2	invoice for Royalty	4
	 	 	 	 
	 	5.3	Timing of Payments	5
	 	 	 	 
	 	5.4	Method of Payments	5
	 	 	 	 
	6.	Reporting, books
    and records	5
	 	 	 	 
	 	6.1	Obligation to keep books and records	5
	 	 	 	 
	 	6.2	Reporting	5
	 	 	 	 
	7.	Right of Audit	5
	 	 	 	 
	 	7.1	Royalty Audit	5
	 	 	 	 
	 	7.2	Adjustment	6
	 	 	 	 
		7.3	Costs of the Audit	6
	 	 	 	 
	8.	Goods and Services
    Tax (GST)	6
	 	 	 	 
	 	8.1	Preliminary	6
	 	 	 	 
	 	8.2	GST exclusive	6
	 	 	 	 
	 	8.3	Liability to pay GST	6
	 	 	 	 
	 	8.4	Tax Invoice	6
	 	 	 	 
	 	8.5	Adjustment Event	6
	 	 	 	 
	 	8.6	Reimbursement of Expenses	7
	 	 	 	 
		8.7	Non Merger	7
	 	 	 	 
	9.	Dispute Resolution	7
	 	 	 	 
	 	9.1	Interpretation	7
	 	 	 	 
	 	9.2	No Proceedings	7
	 	 	 	 
	 	9.3	Dispute Notice	7
	 	 	 	 
	 	9.4	Determination of a Matter by Expert	7
	 	 	 	 
	 	9.5	Other Dispute Procedure	8
	 	 	 	 
	 	9.6	Compliance with Agreement	9
	 	 	 	 
	10.	Late payment	9

 

    	 

    	 

    

 

	 	10.1	interest	9
	 	 	 	 
	11.	Assignment	9
	 	 	 
	 	11.1	No
    assignment	9
	 	 	 	 
	 	11.2	Restriction
    on sale	9
	 	 	 	 
	 	11.3	Ownership
    of the Company	9
	 	 	 	 
	12.	Publicity
    and confidentiality	9
	 	 	 
	 	12.1	Announcements	9
	 	 	 	 
	 	12.2	Publicity	9
	 	 	 	 
	 	12.3	Confidentiality	10
	 	 	 	 
	13.	Notices	10
	 	 	 
	 	13.1	Form
    of notice	10
	 	13.2	Receipt	10
	 	 	 	 
	 	13.3	Address
    for notices	11
	 	 	 	 
	14.	General	11
	 	 	 
	 	14.1	Entire
    agreement	11
	 	 	 	 
	
	14.2	Variation	11
	 	 	 	 
	 	14.3	Costs
    and expenses	11
	 	 	 	 
	 	14.4	Waiver	12
	 	 	 	 
	 	14.5	Severance	12
	 	 	 	 
	 	14.6	Counterparts	12
	 	 	 	 
	 	14.7	Further
    assurances	12
	 	 	 	 
	 	14.8	Governing
    law and jurisdiction	12

 

    	 

    	 

    

 

	Royalty Agreement 	EMIL Ebsworth

 

Royalty
Agreement

 

Date

 

Parties

 

Bioxyne Limited ACN
084 464 193 of Suite 404, 25 Lime Street, Sydney NSW 2000

 

(Bioxyne)

 

Mariposa Health Limited
ACN 134 154 680 of Suite 6, 61 Avalon Parade, Avalon Beach NSW 2107

 

(Mariposa)

 

Hunter Immunology Pty
Limited ACN 106 556 094 of c/- Traverse Accountants, Suite 404, 25 Lime Street, Sydney NSW 2000

 

(Company)

 

Recitals

 

		A,	In
                                         accordance with the terms of a Share Sale and Purchase Agreement dated on or about the
                                         same date as this Agreement, Bioxyne sold all of the shares in the capital of the Company
                                         to Mariposa.

 

		B.	The
                                         Company is the holder of all the Intellectual Property Rights.

 

		C.	Mariposa
                                         operates a pharmaceuticals development business and Mariposa wishes to augment its business
                                         with the purchase of the Company and its Intellectual Property Rights.

 

		D.	It
                                         is a condition precedent of the Share Sale and Purchase Agreement (SSPA) that
                                         the Boards of Bioxyne and Mariposa each approve the entry into this Agreement. Further,
                                         each of the parties is obliged under the SSPA to deliver executed versions of this Agreement
                                         at Completion (as that term is defined under the SSPA).

 

The
parties agree, in consideration of, among other things, the mutual promises contained in this Agreement as follows:

 

		1.	Definitions
                                         and interpretation

 

		1.1	Definitions

 

In this Agreement, unless
the context requires otherwise:

 

Agreed Rate means
a rate of interest which is 2% per annum above the Bank Bill Rate;

 

    	 

    	 

    

  

ASIC
means the Australian Securities and Investments Commission;

 

ASX
means ASX Limited ACN 008 624 691 or the securities exchange market operated by the ASX, as the context requires;

 

ASX
Listing Rules means the official listing rules issued and enforced by the ASX as amended from time to time;

 

Bank
Bill Rate means the Australian 3 month Bank Bill Swap Reference Mid Rate specified by Reuters Monitor Service Page BBSY at
or about 10:00 am (Sydney time) on the first Business Day of each month, provided that, if the Bank Bill Rate cannot be so determined,
the Bank Bill Rate will mean the rate (expressed as a percentage yield per annum to maturity) quoted at or about such time by
Westpac Banking Corporation as the rate at which it would be prepared to purchase bills of exchange accepted by an Australian
trading bank and having a tenor of 90 days and of an amount of $100,000;

 

Business
Day means a day on which banks are open for business in the State of New South Wales, Australia, excluding a Saturday, Sunday
or public holiday;

 

Claim
means any allegation, debt, cause of action, Liability, claim, proceeding, suit or demand of any nature howsoever arising
and whether present or future, fixed or unascertained, actual or contingent, whether at law, in equity, under statute or otherwise;

 

Corporations Act means
Corporations Act 2001 (Cth);

 

Duty
means any stamp, transaction or registration duty or other similar charge imposed by any Government Agency and includes, without
limitation, any interest, fine, penalty, charge or other amount imposed in respect of the above but excludes any tax;

 

Expert means an
independent expert appointed under clause 9;

 

Government
Agency means any government, governmental, semi-governmental, administrative, fiscal, judicial or regulatory body, court,
department, commission, authority, tribunal, agency or entity in any relevant jurisdiction;

 

Gross
Revenue means, in clause 4.2(b), all ex-factory sales revenues received by the Company, Mariposa, or a Related Entity from
a sale of a Product, after deduction of the following items, provided and to the extent such items are actually incurred and do
not exceed reasonable and customary amounts in each market in which such sales occurred:

 

		(a)	material
                                         costs;

 

		(b)	trade
                                         and quantity discounts and rebates;

 

		(c)	customer
                                         rebates;

 

		(d)	credits
                                         or allowances made for rejection or return of Products;

 

		(e)	any
                                         tax or government charge levied on the sale, such as goods and services or value added
                                         tax (but not including income tax); and

 

any charges for freight
or insurance;

 

Hi-164
Oral Vaccine means the Company's oral vaccine (proposed to be developed) which uses the application of mucosal immunology
to treat common human diseases and which works by controlling bacterial infections of airways damaged by toxins, and which is
supported by the Patents;

 

Immediately
Available Funds means cash, bank cheque or such other method agreed by the parties;

 

    	 

    	 

    

 

Intellectual
Property means all intellectual property rights including current and future registered and unregistered rights in respect
of copyright, designs, circuit layouts, trade marks, trade secrets, know-how, confidential information, patents (including the
Patents), invention and discoveries and all other intellectual property as defined in Article 2 of the Convention Establishing
the World Intellectual Property Organisation 1967 including as expressed in all reports, clinical trial documents and correspondence
relating to the HI-164 Oral Vaccine;

 

Intellectual Property
Rights means any right or interest in the intellectual Property;

 

Liability
means any debt or other monetary liability or penalty, fine or payment or any liabilities (whether actual, contingent or prospective),
losses, damages, costs and expenses of whatsoever nature or description including without limitation, any loans;

 

Patents means the
patents listed in Schedule 1;

 

Product is a product
that is based, wholly or partly, on the intellectual Property Rights;

 

Proposed
Transaction means the proposed transaction whereby Bioxyne sells all of its shares in the capital of the Company to Mariposa;

 

Quarter
means each 3 month period ending on 31 March, 30 June, 30 September and 31 December, as the case may be;

 

Related Body Corporate
has the same meaning as defined in the Corporations Act;

 

Related
Entity means a related entity of the Company or Mariposa, as that term is defined in the Corporations Act;

 

Royalty means a
royalty calculated in accordance with clause 4; and

 

Ultimate
Holding Company has the same meaning as that term is defined in the Corporations Act.

 

		1.2	interpretation

 

In this Agreement, unless
the context requires otherwise:

 

		(a)	headings
                                         and italicised, highlighted or bold type do not affect the interpretation of this Agreement;

 

		(b)	the
                                         singular includes the plural and the plural includes the singular;

 

		(c)	a
                                         gender includes all other genders;

 

		(d)	other
                                         parts of speech and grammatical forms of a word or phrase defined in this the have a
                                         corresponding meaning;

 

		(e)	a
                                         reference to a "person" includes any individual, firm, company, partnership,
                                         joint venture, an unincorporated body or association, trust, corporation or other body
                                         corporate and any Government Agency (whether or not having a separate legal personality);

 

		(f)	a
                                         reference to any thing (including any right) includes a part of that thing, but nothing
                                         in this clause 1.2(f) implies that performance of part of an obligation constitutes performance
                                         of the obligation;

 

		(g)	a
                                         reference to a clause, party, annexure, exhibit or schedule is a reference to a clause
                                         of, and a party, annexure, exhibit and schedule to, this Agreement and a reference to
                                         this Agreement includes any clause, annexure, exhibit and schedule;

 

    	 

    	 

    

 

		(h)	a
                                         reference to a document (including this Agreement) includes all amendments or supplements
                                         to, or replacements or novations of, that document;

 

		(i)	a
                                         reference to a party to any document includes that party's successors and permitted assigns;

 

		(j)	a
                                         reference to time is to Sydney time;

 

		(k)	the
                                         word person means a natural person and any association, body or entity whether
                                         incorporated or not;

 

where
any word or phrase is defined, any other part of speech or other grammatical form of that word or phrase has a cognate meaning;

 

		(m)	a
                                         reference to "$", "A$", "dollars" or "Dollars"
                                         is a reference to the lawful currency of the Commonwealth of Australia;

 

		(n)	a
                                         covenant or agreement on the part of two or more persons binds them jointly and severally;

 

		(0)	no
                                         rule of construction applies to the disadvantage of a party because this Agreement is
                                         prepared by (or on behalf of) that party;

 

		(p)	"Includes",
                                         "such as", and "for example" and similar words and phrases are not
                                         to be construed as words or phrases of limitation; and

 

		(q)	a
                                         reference to any thing is a reference to the whole and each part of it.

 

		1.3	Business
                                         Day

 

If
anything under this Agreement is required to be done by or on a day that is not a Business Day that thing must be done by or on
the next Business Day.

 

		2.	Commencement

 

This
Agreement commences on the date of this Agreement or the date of completion of the Proposed Transaction, whichever is earlier.
If the Proposed Transaction does not complete, this Agreement is void from the date of commencement.

 

		3.	Mariposa

 

Mariposa
must ensure and procure that the Company complies with its obligations under this Agreement.

 

		4.	Royalties

 

		4.1	Obligation
                                         to Pay Royalties

 

The
Company must pay, and Mariposa guarantees the payment of, the Royalties to Bioxyne, in the manner set out in this Agreement. The
Royalties will not be reduced by claims that other intellectual property rights were required in order to receive revenue on which
the Royalties are calculated.

 

		4.2	Royalties

 

		(a)	If
                                         the Intellectual Property Rights are sold or licensed to a third party (in accordance
                                         with this Agreement), the Royalties are calculated as 6,5% of the gross revenue received
                                         by the Company, Mariposa, or a Related Entity in respect of the sale or sub-licensing
                                         of the Intellectual Property Rights, including any sale proceeds or sub-royalties.

 

    	 

    	 

    

 

		(b)	To
                                         the extent the Company, Mariposa, or a Related Entity, manufactures Products based on
                                         the Intellectual Property Rights, the Royalties are calculated as 2% of Gross Revenue.

 

		(c)	For
                                         the avoidance of doubt, it is possible for Royalties to be payable simultaneously under
                                         clauses 42(a) and 42(b).

 

		4.3	Combined
                                         intellectual property

 

If
the Company, Mariposa or a Related Entity commercialises a Product which combines the Intellectual Property with other intellectual
property, the Bioxyne is entitled to Royalties in the same proportion as the Intellectual Property, as compared to the other intellectual
property, contributes to the value of the Product.

 

Note:
For example, assume that the Company manufactures a Product to which the Intellectual Property contributes 70% of the value and
other intellectual property contributes 30% of the value. Bioxyne would be entitled to 2% of 70% of the Gross Revenue from the
Product

 

		4.4	Revenues
                                         other than cash

 

If
the Corripany, Mariposa, or any Related Entity sells, licenses, transfers, provides or otherwise makes available to any third
party any Intellectual Property Rights or Products that are subject to the Royalty provisions in this Agreement:

 

		(a)	in
                                         return for non-cash consideration; or

 

		(b)	in
                                         a transaction that is not an arm's length commercial transaction; then the applicable
                                         Royalties due under this Agreement shall be based on:

 

		(c)	with
                                         respect to 4.4(a) above, the fair market value of such non-cash consideration; and

 

		(d)	with
                                         respect to 4.4(b) above, the list price for such Products or, if there is no applicable
                                         list price, then a price which would normally be charged by such party in an arms length
                                         transaction to independent third parties making similar commitments (if applicable).

 

		5.	Payment
                                         of Royalty

 

		5.1	Notification
                                         of Royalty

 

		(a)	Within
                                         10 Business Days after the end of each Quarter in which a Royalty was payable, the Company
                                         must notify Bioxyne of the Royalties payable for that Quarter.

 

		(b)	At
                                         the same time, the Company will provide to Bioxyne a report containing such details in
                                         respect of how the Royalties have been calculated as agreed between the parties.

 

		5.2	Invoice
                                         for Royalty

 

		(a)	Bioxyne
                                         must provide the Company with a tax invoice (to satisfy the GST Act) in respect of the
                                         amount of Royalty payable for a Quarter, which amount is either:

 

		(i)	the
                                         amount included in the notice from the Company under clause 5.1; or

 

		(ii)	if
                                         the Company does not provide the notice required under clause 5.1, an estimate of the
                                         Royalty, based on an average of the previous four Quarters' Royalties.

 

    	 

    	 

    

 

		(b)	If
                                         Bioxyne issues an invoice in accordance with clause 5.2(a)(ii) and the amount invoiced
                                         is not accurate (for example, based on the results of the audit under clause 7.1 or information
                                         subsequently obtained or provided to Bioxyne), then:

 

		(i)	Bioxyne
                                         must, as soon as reasonably practicable, issue an amended tax invoice;

 

		(ii)	if
                                         there has been an overpayment of Royalties, within 10 Business Days of the date of the
                                         amended invoice, Bioxyne must repay that amount to Company (with interest calculated
                                         in accordance with clause 10 and from the date the Royalty was received until the date
                                         Bioxyne repays that amount); and

 

		(iii)	if
                                         there has been an underpayment of Royalties, within 10 Business Days of receipt by the
                                         Company of the amended invoice, the Company must repay that amount to Bioxyne (with interest
                                         calculated in accordance with clause 10 from the date the Royalty was payable under clause
                                         5.3 until the date of the amended invoice, such interest to be paid by the Company).

 

		5.3	Timing
                                         of Payments

 

The Royalty must be paid
on the earlier of:

 

		(a)	the
                                         date that is 30 days after the end of each Quarter; and

 

		(b)	5
                                         Business Days after the receipt by the Company of Bioxyne's invoice under clause 5.2,

 

		5.4.	Method
                                         of Payments

 

Until
Bioxyne otherwise advises in writing, the Company must discharge its obligations to pay any Royalty by making those payments to
Bioxyne in Immediately Available Funds or as otherwise directed from time to time by Bioxyne.

 

		6.	Reporting,
                                         books and records

 

		6.1	Obligation
                                         to keep books and records

 

The
Company will keep, and must ensure its Related Bodies Corporate keep, books and records in such reasonable details as will permit
the reports provided for in this Agreement to

be made and the Royalties
and other amounts under this Agreement to be determined.

 

		6.2	Reporting

 

The
Company will provide annual reports to Bioxyne in respect of the Company's, Mariposa's or a Related Entity's activities undertaken
in the last year in relation to the Intellectual Property Rights, such as clinical trials undertaken, any filings or registrations
with regulators, capital expenditures in respect of the Intellectual Property Rights, any commercialisation activities, the appointment
of distributors, or any other matters materially relevant to Bioxyne as the holder of the rights to the Royalties under this Agreement.

 

		7.	Right
                                         of Audit

 

		7.1	Royalty
                                         Audit

 

		(a)	Bioxyne
                                         may require the Company to cause its books and records relating to the revenues
                                         in respect of the Intellectual Property Rights and the Products during that calendar
                                         year, and those of any Related Bodies Corporate, to be made available to an independent
                                         auditor. In this case, the Company must procure that the auditor prepare and deliver
                                         to Bioxyne and Mariposa a certificate in respect of any calendar year showing in respect
                                         of that calendar year in relation to this Agreement any information that Bioxyne may
                                         deem reasonably necessary to ascertain whether the Royalties have been properly calculated
                                         and paid.

 

    	 

    	 

    

 

		(b)	A
                                         certificate provided by the auditor in accordance with clause 7.1 (a) will, in the absence
                                         of manifest error, be binding and conclusive as between the parties.

 

		(c)	The
                                         parties must attempt to agree on the identity of the independent auditor, within 5 Business
                                         Days after the date referred to in clause 7.1(a) and failing agreement, the independent
                                         auditor is to be nominated by the President of the New South Wales Chapter of the Institute
                                         of Chartered Accountants or such person occupying his or her position or performing his
                                         or her role from time to time.

 

		7.2	Adjustment

 

		(a)	Immediately
                                         on receipt of a certificate from the auditor under this clause 7, and in the absence
                                         of manifest error in the certificate, the parties must promptly make such cash payments
                                         between them as may be necessary to ensure that Bioxyne has received the balance (if
                                         any) of any outstanding Royalty for the relevant calendar year, or to ensure that the
                                         Company has received any amount it has overpaid in respect of the Royalty.

 

		(b)	The
                                         Company must ensure that to the extent substantial issues are identified by the auditor
                                         that, in a timely manner, it takes steps to improve the relevant systems and record keeping
                                         to adequately address those issues.

 

		7.3	Costs
                                         of the Audit

 

Any
audit carried out in accordance with clause 7.1 will be paid by Bioxyne, unless the audit reveals substantial issues (including
in respect of the calculation of royalties or record keeping), in which case the Company will pay the cost of the audit.

 

		8.	Goods
                                         and Services Tax (GST)

 

		8.1	Preliminary

 

Words or expressions used
in this clause that are defined in A New Tax System (Goods and Services Tax) Act 1999 (GST Act) have the same meaning
given to them in that Act.

 

		8.2	GST
                                         exclusive

 

Unless
otherwise stated, any amount specified in this Agreement as the consideration payable for any taxable supply does not include
any GST payable in respect of that supply.

 

		8.3	Liability
                                         to pay GST

 

If
a party makes a taxable supply under this Agreement (Supplier), then the recipient of the taxable supply (Recipient)
must also pay, in addition to the consideration for that supply, the amount of GST payable in respect of the taxable supply
at the time the consideration for the taxable supply is payable.

 

		8.4	Tax
                                         Invoice

 

Notwithstanding
the foregoing, the Recipient is not obliged under this Agreement to pay the amount of any GST payable until the Supplier provides
it with a valid tax invoice for the taxable supply.

 

		8,5	Adjustment
                                         Event

 

If
an adjustment event arises in relation to a taxable supply made by a Supplier under this Agreement, the amount paid or payable
by the Recipient pursuant to clause 8.3 will be amended to reflect this and a payment will be made by the Recipient to the Supplier
or vice versa as the case may be.

 

    	 

    	 

    

 

		8.6	Reimbursement
                                         of Expenses

 

If
a third party makes a taxable supply and this Agreement requires a party to this Agreement (the payer) to pay for, reimburse
or contribute to (pay) any expense or liability incurred by the other party to that third party for that taxable supply,
the amount the payer must pay will be the amount of the expense or liability plus the amount of any GST payable in respect thereof
but reduced by the amount of any input tax credit to which the other party is entitled in respect of the expense or liability.

 

		8.7	Non
                                         Merger

 

This
clause does not merge on completion and will continue to apply after expiration or termination of this Agreement.

 

		9.	Dispute
                                         Resolution

 

		91	Interpretation

 

in
this clause 9, the term Dispute means any controversy, Claim or dispute arising out of or in relation to this Agreement
between the parties to this Agreement.

 

		9.2	No
                                         Proceedings

 

		(a)	The
                                         parties agree to use all reasonable efforts to resolve any Dispute.

 

		(b)	Neither
                                         party may start court proceedings (except proceedings seeking injunctive or interlocutory
                                         relief to preserve property or rights or to avoid losses that are not compensable in
                                         damages) in respect of a Dispute unless it has complied with this clause 9.

 

		(c)	In
                                         respect of each payment of Royalty calculated in accordance with clause 3, Bioxyne is
                                         deemed to have accepted the Company's calculation unless Bioxyne gives a Dispute Notice
                                         to the Company within 30 days after the receipt of such Royalty disputing the Company's
                                         calculation.

 

		9.3	Dispute
                                         Notice

 

		(a)	Any
                                         party wishing to claim that a Dispute has arisen must give notice (Dispute Notice)
                                         to each other party to this Agreement (Disputants) giving details of the Dispute.

 

		(b)	If
                                         the Dispute is:

 

		(i)	solely
                                         in respect of a matter involving financial calculations which is capable of determination
                                         by audit or reference to accounting practices, or other specialist technical knowledge
                                         (such as scientific knowledge), and does not involve any issues relating to the interpretation
                                         of this Agreement then the Dispute Notice must call for the submission of the dispute
                                         to an Expert in accordance with clause 9.4; or

 

		(ii)	in
                                         respect of any other matter then the procedure in clause 9.5 must apply.

 

		9.4	Determination
                                         of a Matter by Expert

 

		(a)	The
                                         parties must attempt to agree on the identity of the Expert within 5 Business Days after
                                         the date of the Dispute Notice and failing agreement, the Expert is to be nominated by
                                         the President of the New South Wales Chapter of the Institute of Chartered Accountants
                                         or such person occupying his or her position or performing his or her role from time
                                         to time. If the parties agree the President of the New South Wales Chapter of the Institute
                                         of Chartered Accountants is not suitable to select a relevant Expert for a certain Dispute,
                                         the parties may ask another person to nominate an Expert for them.

 

    	 

    	 

    

 

		(b)	The
                                         Expert appointed by the parties or nominated under clause 9.4(a) must have reasonable
                                         commercial, practical and technical experience in the area of dispute.

 

		(C)	The
                                         Expert must:

 

act as an expert and
not as an arbitrator;

 

		(ii)	accept
                                         submissions from the parties as to the subject matter of the dispute within 14 days after
                                         his or her appointment;

 

		(iii)	state
                                         his or her determination of the dispute in writing within 28 days after his or her appointment
                                         but need not give reasons; and

 

		(iv)	undertake
                                         to keep confidential all matters coming to his or her knowledge by reason of his or her
                                         appointment.

 

		(d)	The
                                         determination of the Expert is final and binding on the parties other than in the case
                                         of fraud or manifest error.

 

		(e)	To
                                         the extent the Expert is requested to make a determination in respect of Royalty amounts:

 

if
the Royalty determined to be payable by the Expert is greater than the amount actually paid in respect of the disputed Royalty
payment, the Company must pay Bioxyne the difference within 7 days after the handing down of the Expert's determination;

 

		(ii)	if
                                         the Royalty determined to be payable by the Expert is less than the disputed amount,
                                         Bioxyne must refund the difference to the Company within 7 days after the handing down
                                         of the Expert's determination; and

 

		(iii)	if
                                         the Royalty determined as payable by the Expert exceeds the amount actually paid, the
                                         Company must bear the costs of the Expert and if the Royalty determined as payable by
                                         the Expert does not exceed the amount actually paid by the Company, Bioxyne must bear
                                         the costs of the Expert.

 

		9.5	Other
                                         Dispute Procedure

 

		(a)	The
                                         procedure that is to be followed to settle a Dispute (other than a Dispute dealt with
                                         in accordance with clause 9.4) the subject of a Dispute Notice is as follows:

 

		(i)	first,
                                         negotiation by senior representatives under clause 9.5(b); and

 

		(ii)	second,
                                         negotiation of senior executives under clause 9.5 (c).

 

		(b)	During
                                         the 10 Business Day period a Dispute Notice is given under clause 9.3 or such longer
                                         period unanimously agreed in writing by the Disputants (Initial Period), a
                                         senior representative of each Disputant (with authority to settle the Dispute) must use
                                         their reasonable efforts to resolve the Dispute.

 

		(c)	If
                                         the Disputants are unable to resolve the Dispute within the Initial Period, each Disputant
                                         agrees that the Dispute must, at the request of any Disputant, be referred to the respective
                                         senior executive of the Ultimate Holding Company of each Disputant or, in the case of
                                         any Disputant (such as the CEO or Managing Director) which does not have an Ultimate
                                         Holding Company, its own senior executive. A joint unanimous determination of the Dispute
                                         in writing by the senior executives within 20 Business Days after the request of any
                                         Disputant to refer the Dispute to the senior executives (or such longer period unanimously
                                         agreed in writing by the Disputants) shall be final and binding on the Disputants.

 

    	 

    	 

    

 

		9.6	Compliance
                                         with Agreement

 

Until the Dispute is resolved,
the Disputants must continue to observe their obligations under this Agreement in a timely manner.

 

		10.	Late
                                         payment

 

		10.1	Interest

 

		(a)	If
                                         a party fails to pay an amount payable under this Agreement by the due date, the party
                                         must pay interest on the amount from the time the amount falls due to the date of actual
                                         receipt by the party to which it is owing (both dates exclusive).

 

		(b)	Interest
                                         will be calculated at the Agreed Rate applicable on the due date for payment of the relevant
                                         amount.

 

		11.	Assignment

 

		11.1	No
                                         assignment

 

Neither
party may assign its interest or obligation under this Agreement without the prior written approval of the other party, and such
approval may be subject to conditions.

 

		11.2	Restriction
                                         on sale

 

The
Company must not sell or sub-licence the Intellectual Property Rights without the prior written consent of Bioxyne (such consent
not to be unreasonably withheld).

 

		11.3	Ownership
                                         of the Company

 

		(a)	Mariposa
                                         must not transfer any shares or other securities in the capital of the Company (other
                                         than to a Related Body Corporate) without the prior written consent of Bioxyne (such
                                         consent not to be unreasonably withheld).

 

		(b)	The
                                         Company must not issue any shares or other securities in the capital of the Company (other
                                         than to a Related Body Corporate) without the prior written consent of Bioxyne (such
                                         consent not to be unreasonably withheld).

 

		12.	Publicity
                                         and confidentiality

 

		12.1	Announcements

 

in consideration of each
party entering into and performing their respective obligations under, and in accordance with the provisions of, this Agreement,
each party agrees, except as required by law or by the ASX Listing Rules (if applicable) that:

 

		(a)	the
                                         terms of this Agreement are to be kept confidential and released to persons who are not
                                         a party to this document (other than the professional advisers to the parties) only by
                                         the prior mutual written consent of the parties; and

 

		(b)	no
                                         party shall make any press release in relation to this Agreement without the prior consent
                                         in writing of the other party.

 

		12.2	Publicity

 

No public announcement
or communication relating to the negotiations of the parties or the subject matter or terms of this Agreement is to be made or
authorised by or on behalf of any party without the prior written approval of the other party.

 

    	 

    	 

    

 

		12.3	Confidentiality

 

Each
party agrees with the other party that all information in relation to the other party's business including, without limitation,
any intellectual property, trade secrets, operations, know-how, or any information concerning the organisation, management and
finance of the other party, which is exchanged between them during the negotiations prior to the Completion Date or in the course
of any party performing its duties or obligations under the provisions of this Agreement, is confidential and shall not be disclosed,
divulged or otherwise placed at the disposal of any person not being a party to this Agreement or a Related Body Corporate of
a party except:

 

		(a)	to
                                         employees, legal advisers, auditors and other consultants requiring the information for
                                         the purpose of this Agreement;

 

		(b)	with
                                         the consent of the party who supplied the information;

 

		(c)	if
                                         the information is, prior to the commencement of this Agreement, lawfully in the possession
                                         of the recipient of the information through sources other than the party who supplied
                                         the information;

 

		(d)	if
                                         required by law or the ASX;

 

		(e)	if
                                         strictly and necessarily required in connection with legal proceedings; and

 

		(f)	if
                                         the information is or becomes generally and publicly available other than through the
                                         default of a party who divulges the information.

 

		13.	Notices

 

		13.1	Form
                                         of notice

 

All
notices, requests, demands, consents, approvals, agreements or other communications (notices) to or by a party given for
the purposes of Agreement must be:

 

		(a)	in
                                         writing;

 

		(b)	signed
                                         by the party giving notice or a person duly authorised by that party or, where transmitted
                                         by e-mail, sent by the party giving notice or a person duly authorised by that party;

 

		(c)	directed
                                         to the recipient's address (as specified in clause 13.3 or as varied by any notice);
                                         and

 

		(d)	hand
                                         delivered, sent by prepaid post or transmitted by email or facsimile to that address,

 

and
will be taken to be duly given or made (in the case of delivery in person or by post or email or facsimile transmission) when
delivered, received or left at the address of the recipient

shown in this Agreement
or to any other address which it may have notified the sender.

 

		13.2	Receipt

 

A notice given in accordance
with this clause is taken as having been given and received:

 

		(a)	if
                                         hand delivered at or before 4.00 pm on a Business Day, on delivery, otherwise at 9.30
                                         am on the next Business Day;

 

		(b)	if
                                         sent by prepaid post, on the seventh Business Day after the date of posting;

 

		(c)	if
                                         transmitted by e-mail, on the first Business Day after the date of transmission; or

 

    	 

    	 

    

 

		(d)	if
                                         transmitted by facsimile at or before 4.00 pm on a Business Day, at the time recorded
                                         on the transmission report indicating successful transmission of the entire notice, otherwise
                                         at 9.30 am on the next Business Day.

 

		13.3	Address
                                         for notices

 

Unless
varied by notice in accordance with this clause 13.3, the parties' addresses and other details are:

 

	(a)	if to Bioxyne: 

 

	Address:	Suite 404, 25 Lime Street, Sydney
    NSW 2000
	 	 
	Email:	tong ho@bigpond.corn
	 	 
	Attention:	Anthony Ho 

 

	(b)	if to Mariposa:

 

	Address:	Suite 6, 61 Avalon. Parade, Avalon
    Beach
		NSW 2107
	 	 
	Email:	pcomarisPmaribosahealth.com.au 
	 	 
	Attention:	Phillip Comans

 

	(c)	if to the Company:  

 

	Address: 	of- Traverse Accountants, Suite 404, 25 Lime Street, Sydney
    NSW 2000  
	 	 
	Email:	pcomansOmariposaheaith.com.au  
	 	 
	Attention:	Phillip Comans

 

		14.	General

 

		14.1	Entire
                                         agreement

 

This
Agreement states all of the express terms of the agreement between the parties in respect of its subject matter. It supersedes
all prior discussions, negotiations, understandings and agreements in respect of its subject matter.

 

		14.2	Variation

 

A
variation of any term of this Agreement will be of no force or effect unless it is in writing and signed by each of the parties.

 

		14.3	Costs
                                         and expenses

 

		(a)	Mariposa
                                         must pay any Duty in respect of the execution, delivery and performance of this Agreement
                                         and any agreement or document entered into or signed under this Agreement.

 

		(b)	Subject
                                         to clause 14.3(a) and any other term of this Agreement, each party must pay its own costs
                                         and expenses in respect of the negotiation, preparation, execution, delivery and registration
                                         of this Agreement or other agreement or document described in clause 14.3(a)

 

    	 

    	 

    

 

		(c)	Any
                                         action to be taken by a party in performing its obligations under this Agreement must
                                         be taken at its own cost and expense unless otherwise provided in this Agreement.

 

		14.4	Waiver

 

		(a)	A
                                         party may not rely on the words or conduct (including a delay in the exercise, a non-exercise
                                         or a partial exercise of a right) of the other party as a waiver of any right arising
                                         under or in connection with this Agreement (including a right to rely on this clause)
                                         unless the waiver is in writing and signed by the party granting the waiver.

 

		(b)	In
                                         clause 14.4(a) the term waiver is
                                         intended to include an election between rights and remedies as well as conduct which
                                         might otherwise give rise to an estoppel.

 

		(c)	A
                                         waiver is only effective in relation to the particular obligation or breach in respect
                                         of which it is given and is not to be taken as an implied waiver of any other obligation
                                         or breach or as an implied waiver of that obligation or breach in relation to any other
                                         occasion.

 

		14.5	Severance

 

		(a)	If
                                         a provision in this Agreement is wholly or partly void, illegal or unenforceable in any
                                         relevant jurisdiction that provision or part must, to that extent, be treated as deleted
                                         from this Agreement for the purposes of that jurisdiction. This does not affect the validity
                                         or enforceability of the remainder of the provision or any other provision of this Agreement.

 

		(b)	Clause
                                         14.5(a) does not apply and has no effect if severance of the provision of this Agreement
                                         in accordance with clause 14.5(a) materially affects or alters the nature or effect of
                                         the parties' obligations under this Agreement.

 

		14.6	Counterparts

 

		(a)	This
                                         Agreement may be executed in any number of counterparts, each signed by one or more parties.
                                         Each counterpart when so executed is deemed to be an original and all such counterparts
                                         taken together constitute one document.

 

		(b)	A
                                         party that has executed a counterpart of this Agreement may exchange that counterpart
                                         with another party by faxing it to the other party and, if that other party requests
                                         it, promptly delivering that executed counterpart by hand or post to the other party.
                                         However, the validity of this Agreement is not affected if the party who has faxed the
                                         counterpart delays in delivering or does not deliver it by hand or by post.

 

		14.7	Further
                                         assurances

 

Each party must, at its
own expense, do all things and execute all further documents necessary to give full effect to this Agreement and the transactions
contemplated by it.

 

		14.8	Governing law and jurisdiction

 

		(a)	This
                                         Agreement is governed by and is to be construed under the laws in force in New South
                                         Wales.

 

		(b)	Each
                                         party irrevocably submits to the non-exclusive jurisdiction of the courts exercising
                                         jurisdiction in New South Wales and courts of appeal from them in respect of any proceedings
                                         arising out of or in connection with this Agreement. Each party irrevocably waives any
                                         objection to the venue of any legal process in these courts on the basis that the process
                                         has been brought in an inconvenient forum.

 

    	 

    	 

    

 

 

 

    	 

    	 

    

 

	Executed as an agreement	 	 
	 	 	 
	Executed by Bioxyne Limited ACN 084 464 193 in accordance
    with section 127(1) of the Corporations Act 2001 (Cth) by:	 	 
	 	 	 
	/s/ Anthony
    Ho	 	/s/ Jarrod T White
	Signature of Director	 	Signature of Director/Company Secretary
	 	 	 
	Anthony
    Ho	 	Jarrod
    T WhitE
	Full Name (print)	 	Full Name (print)
	 	 	 
	Executed by Mariposa Health Limited ACN 134 154 680
    in accordance with section 127(1) of the Corporations Act 2001 (Cth) by:	 	 
	 	 	 
	/s/ Phillip Comans	 	/s/ Kevin Lynn
	Signature of Director	 	Signature of Director/Company Secretary
	 	 	 
	Phillip Comans	 	Kevin
    Lynn
	Full Name (print)	 	Full Name (print)
	 	 	 
	Executed by Hunter Immunology Pty Limited ACN 106 556
    094 in accordance with section 127(1) of the Corporations Act 2001 (Cth) by:	 	 
	 	 	 
	/s/ Anthony HO	 	/s/ Jarrod T White
	Signature of Director	 	Signature of Director/Company Secretary
	 	 	 
	Anthony
    Ho	 	Jarrod
    T WhitE
	Full Name (print)	 	Full Name (print)

 

    	 

    	 

    

 

	Share Sale and Purchase Agreement	HWL Ebsworth

 

Annexure
C - List of Liabilities

 

Being the Trade Creditors reconciliation
below:

 

Hunter Immunology
Pty Limited

Suite 1005

4 Bridge Street

Sydney NSW 2000

 

Payables
Reconciliation [Summary]

 

24/02/2014

 

	 2410212014

        2:03 PM

        Dante
	 	Total
    Due	 	 	0
    - 30	 	 	31
    - 60	 	 	61-90	 	 	Page
    I 90+	 
	Alder IP Pty Ltd	 	$	425.30	 	 	$	425.30	 	 	$	0.00	 	 	$	0.00	 	 	$	0.00	 
	Datapharm Australia	 	$	5,049.00	 	 	 	50.00	 	 	$	0.00	 	 	$	0.00	 	 	 	55,049.00	 
	Institute for Breathing &
    Sleep	 	$	825.00	 	 	$	0.00	 	 	$	0.00	 	 	$	0.00	 	 	$	025.00	 
	Lanza-Sales Ltd	 	$	66,143.40	 	 	$	0.00	 	 	$	0..00	 	 	$	0.00	 	 	$	66,143.40	 
	Total:	 	$	72,442.70	 	 	$	425.30	 	 	$	0.00	 	 	$	0.00	 	 	$	72017.40	 
	Ageing Percent	 	 	 	 	 	 	0.6	%	 	 	0.0	%	 	 	0.0	%	 	 	99.4	%
	Payables Account	 	$	72,442.70	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Out of Balance
    Amount	 	$	0.00	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 

 

Being the ongoing payments to contracted
suppliers below:

 

		1.	Alder
                                         IP Pty Ltd as the appointed legal/patent manager and related patent/IP disbursements
                                         and service providers as engaged on the companies behalf in other jurisdictions by Alder
                                         IP;

		2.	Fort
                                         Knox Records Management as the company's archiving service that contains HIL owned
                                         data. This incurs - $60 + GST p/month charge and it is noted that there would be costs
                                         in addition to this for data access/retrieval/disposal as is standard with all other
                                         data carriers;

		3.	Iron
                                         Mountain Australia - archiving service for older company records based in Melbourne.
                                         This incurs - $220 + GST p/month charge and it is noted that there would be costs in
                                         addition to this for data access/retrieval/disposal as is standard with all other data
                                         carriers;

		4.	Grantchester
                                         Financial Services Pty Ltd - Lease of Suite 1001, 4 Bridge Street Sydney NSW 2000.
                                         This is -$1500 + GST p/month which at the date of agreement is prior registered office
                                         of the company and contains some materials. Noted the short term intention is to give
                                         notice to vacate this premises;

		5.	Interactive
                                         investor - manages the company website - note this and the domain name are sold as
                                         property of the company therefore any changes from this service and any charges are the
                                         financial responsibility of the new owners of the company;

		6.	Pacnet
                                         - web hosting $85 per/month inc GST;

		7.	Remektek
                                         Egnyte data store for HIL data room. Noted this is -$1200 p.a + hourly costs of Paul
                                         Szilard to maintain. This data and service is sold with the Company and hence any charges
                                         to maintain or recover the data base pass to the new owner.

		8.	ASICIATO
                                         - as required for annual registration and ongoing fees. All liabilities at date are
                                         disclosed.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]